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ABSTRACT 
 Dysregulated Hippo pathway signaling promotes the onset of aggressive 
cancers through the induced nuclear activity of yes-associated protein (YAP) and 
transcriptional co-activator with PDZ binding motif (TAZ) (YAP/TAZ). Uncontrolled 
nuclear YAP/TAZ activity evokes tumor-initiating properties in a range of epithelial-
derived cancers, including oral and breast cancers, but their downstream targets 
and mechanisms of action are unclear. Recent studies have suggested that the 
pro-tumorigenic roles for YAP/TAZ relate to their convergence with growth factor 
signaling pathways. Based on these previous studies, I hypothesized that 
YAP/TAZ driven transcription contributes to carcinoma progression, and that 
cooperation with transforming growth factor β (TGFβ)-induced signals promotes 
aggressive oncogenic traits. In this thesis I show that dysregulated YAP 
localization precedes oral squamous cell carcinoma (OSCC) development, and 
that nuclear YAP/TAZ activity drives cell proliferation, survival, and migration in 
vitro, and is required for tumor growth and metastasis in vivo. Global gene 
expression studies in OSCC cells revealed that YAP/TAZ-mediated gene 
expression correlates with expression changes that occur in human OSCCs 
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identified by “The Cancer Genome Atlas” (TCGA), many of which encode cell cycle 
and survival regulators. By exploring the relationship with growth factor signaling, 
I found that YAP/TAZ induce pro-tumorigenic events by converging with TGFβ-
induced signals, particularly in breast cancer cells where TGFβ is known to 
promote metastatic properties. My observations indicated that YAP/TAZ are 
necessary for maintaining and promoting TGFβ-induced tumorigenic phenotypes 
in breast cancer cells, and that these phenotypes result from the cooperative 
activity of YAP/TAZ, the TEA domain family of transcription factors (TEADs), and 
TGFβ-activated SMAD2/3 in the nucleus. Genome-wide expression analyses 
indicated that YAP/TAZ, TEADs, and TGFβ-induced signals coordinate a specific 
pro-tumorigenic transcriptional program. Importantly, genes cooperatively 
regulated by these complexes, such as the novel targets neuronal growth regulator 
1 (NEGR1) and urothelial cancer associated 1 (UCA1), are necessary to maintain 
tumorigenic activity in metastatic breast cancer cells. Nuclear YAP/TAZ also 
cooperate with TGFβ signaling to promote phenotypic and transcriptional changes 
in non-tumorigenic cells to overcome TGFβ-mediated growth inhibition. This work 
thus defines novel roles for YAP/TAZ in cancer, offering molecular mechanisms 
that may be useful for identifying and targeting YAP/TAZ-driven cancers. 
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CHAPTER I - INTRODUCTION 
Disclaimer: Sections of this chapter are adapted from Hiemer, S. E., and Varelas, 
X. (2012) Stem cell regulation by the Hippo pathway. Biochimica et Biophysica 
Acta (1) license number #3651551200333 from Elsevier Limited. 
Epithelial cancers 
Hallmarks of cancer and the tumor microenvironment 
Cancers are the second leading cause of death in the United States (2). A 
vast majority of tumors (90%) arise from the epithelium and are classified as 
carcinomas (3). Epithelial tissue, one of the four main tissue types, is comprised 
of the cells lining the inside and outside of the body and can be further categorized 
based on cell shape (e.g. cuboidal, squamous) and tissue structure (e.g. simple, 
stratified) (Figure 1.1). Tumorigenesis is considered a multistep disease (Figure 
1.1) and understanding the molecular pathways responsible for initiation and 
progression is important in developing and applying effective therapeutics (4). The 
acquisition of specific “hallmarks” is widely accepted to be fundamental in cancer 
development (5). These characteristics illustrate the complexity of the disease and 
highlight both intra- and extra-cellular traits of the tumor. For instance, the cell 
becomes immortal and continually proliferates, resists cell death and growth 
suppressive cues, and evades the immune system. These attributes are supported 
through increased nutrient availability by angiogenesis and deregulation of cellular 
metabolism. Aggressive properties are also acquired such as the ability to invade 
surrounding tissue and metastasize to distant sites. Genomic instability and the 
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Figure 1.1 - Epithelial cancer progression. Tumor initiation and progression occur in a stepwise fashion, through 
the accumulation of mutations that manifest as “hallmarks of cancer.” Carcinomas can arise from a range of normal 
epithelial tissue, like stratified squamous tissue found in the oral cavity to simple cuboidal tissue found in the breast. 
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accumulation of mutations underlie many of these characteristics. In addition, a 
tumor is no longer recognized as simply a homogenous mass of cancer cells but 
instead as a complex organ comprised of several different cell types. Cancer cells, 
cancer stem cells, cancer-associated fibroblasts (CAFs), endothelial cells, 
pericytes, and immune cells, including tumor-associated macrophages, are all 
considered to communicate with one another and perpetuate the tumor 
microenvironment (Figure 1.2) (6). 
Cancer stem cells 
Cancer stem cells (CSCs) are a small subset of cells within a tumor that 
have the distinct ability to self renew and seed the heterogeneous populations 
which comprise the majority of the tumor (7). CSCs are hypothesized to promote 
tumor initiation and progression and have been implicated in chemoresistance and 
tumor relapse suggesting they drive a more aggressive disease state (6,8). CSCs 
do not necessarily originate from stem cell populations in normal tissue and can 
come from differentiated cancer cells populations that have acquired plasticity (9). 
Although the origins of CSC populations are not fully understood, the activation of 
an epithelial-to-mesenchymal transition (EMT) has been shown to confer stem-like 
properties on cancer cells (10-13). EMT occurs when a cell loses its epithelial 
characteristics, in particular cell-cell contacts and polarity, and gains a 
mesenchymal phenotype, allowing the cell to escape the epithelial layer, acquire 
motility, evade apoptotic cues, and invade the basement membrane (14,15). 
Overexpression of factors that promote EMT, such as transcription factors Twist 
  4 
 
 
Figure 1.2 - The tumor microenvironment. The tumor microenvironment is 
complex and composed of several different types of cells. 
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and Snail, or cytokines like TGFβ, can promote tumor-initiating populations 
(11,16). CSCs can be identified and isolated by distinct cell markers, similar to 
normal stem cell populations, however the expression of these markers varies 
depending on context. In breast and head and neck cancers, several CSC markers 
have been described including cell surface glycoproteins cluster of differentiation 
44 (CD44) and cluster of differentiation 24 (CD24), and intercellular protein 
aldehyde dehydrogenase (ALDH) (17-20). 
Cancer characterization, grade v stage 
During diagnosis, tumors are biopsied and evaluated by a pathologist to 
determine the progress of the disease defined by a grade or stage rating. This 
characterization aids physicians in determining the most appropriate treatment 
plan for the patient. Tumor grade refers to how organized the tissue appears, with 
well-differentiated tumors low-grade tumors (i.e. G1 tumors) being most similar to 
normal tissue. The more poorly differentiated or unorganized tumors are classified 
as highest grade, ranging from G2 to G4. Interestingly, high-grade breast cancers 
have a larger CSC population compared to low-grade cancers (21). Stage is also 
used to classify cancer progression and takes into account more aspects of the 
tumor including grade, the size of the primary tumor, and whether the cancer has 
metastasized to local or distant sites in the body. Stage ranges from I - carcinoma 
in situ to IV - distant metastases (22). 
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Oral cancer 
OSCC is a subset of head and neck cancers that arises from the stratified 
squamous oral mucosa. Head and neck cancer is one of the 10 most common 
cancers worldwide and 90% of these are classified as OSCCs (23). These 
carcinomas are sometimes preceded by visible red or white pre-cancerous lesions, 
termed erythroplakias and leukoplakias respectively, and have a better prognosis 
when diagnosed in early stages (24,25). Unfortunately, a majority of oral cancers 
are diagnosed after they have already spread to the surrounding tissue, at which 
point the 5-year survival rates are around 50% (26). These patients do not respond 
well to treatment and have a greater chance of reoccurrence (27). Fortunately 
there is hope as OSCC can be prevented through early detection and reduced 
exposure to high risk-environmental factors such as alcohol and tobacco (28-30). 
Other risk factors include genetic predisposition and HPV status (31). Although 
current treatment options such as surgery, radiation, and chemotherapy have 
improved over the last few decades, targeted therapies are limited and a better 
understanding of molecular subtypes and biomarkers of OSCC is needed. 
The accumulation of genetic mutations and aberrant signaling pathways 
have been implicated in the development and progression of OSCC. Similarly to 
many other cancers, frequent mutations in cell cycle-regulating genes are found in 
OSCC, including the loss of tumor suppressor genes p53 and Rb and activation of 
cyclin D1 (CCND1) (32-34). Mutations in other signaling pathways are also 
associated with OSCC including Notch and epidermal growth factor receptor 
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(EGFR), among many others. Although Notch signaling is complex in the context 
of tumorigenesis, generally loss of function mutations are observed in OSCC 
suggesting its function as a tumor suppressor in this context (35). On the other 
hand, EGFR signaling promotes tumorigenesis and activation occurs most 
commonly through either receptor overexpression or truncation, which leads to 
constitutive signaling (36,37). STAT3 hyperactivation is also associated with 
OSCC and there is evidence that STAT3 can function downstream of EGFR 
signaling (38,39). This is an important point to consider in using targeted EGFR 
therapies such as cetuximab, a recombinant monoclonal antibody that blocks 
extracellular EGFR from binding ligand, in OSCC treatment, as some tumors may 
not be responsive if downstream effectors are already aberrantly signaling (40). 
Breast cancer 
Breast cancer originates from the breast tissue and is the second leading 
cause of cancer deaths in women (2). It is a heterogeneous disease with tumors 
classified into various histological and molecular subtypes that aid in identification 
and treatment. These subtypes can be broadly defined by the spread of the tumor, 
indicated as either in situ or invasive carcinomas, and by the anatomical 
localization, described for instance as ductal, lobular, tubular, etc. Risk factors for 
developing breast cancer vary by subtype but may include age at menarche, age 
at first live birth, body-mass index, race, and family history (41). The histological 
classification of breast cancers has been in practice for several decades but does 
not take into account recent advances in describing molecular features (42). Gene 
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expression profiling and unbiased hierarchical clustering has resulted in the 
identification of distinct molecular subtypes of breast cancer to include luminal A 
(which make up approximately 40% of all breast cancers), luminal B (20%), triple 
negative/basal-like (15-20%), HER2 type (10-15%), and claudin-low (12-14%) (42-
45). These classifications can be roughly categorized based on the expression of 
several genes including estrogen receptor (ER), progesterone receptor (PR), and 
human epidermal growth factor receptor type 2 (HER2). However, these 
classifications are generalized and can be ambiguous. For instance, luminal 
subtypes are ER and/or PR positive. Luminal A is HER2 negative with low cell 
proliferation whereas luminal B can be HER2 positive or HER2 negative with high 
cell proliferation. Luminal A breast cancers generally have the best prognosis out 
of all the subtypes (43). HER2 subtypes express high levels of HER2 whereas 
triple-negative breast cancers express low levels of ER, PR, or HER2. There is 
approximately 80% overlap between breast cancers that are considered both 
triple-negative and basal-like (46,47). Recently a new subtype has been identified, 
named claudin-low, and is defined as having high expression of EMT markers and 
low expression of luminal differentiation markers (44). The majority of claudin-low 
breast cancers are also considered triple-negative (48). HER2, triple-
negative/basal-like, and claudin-low subtypes all have a higher incidence of CSC 
markers, such as CD44high/CD24low and ALDH1, compared to luminal tumors 
(44,49). These breast cancers also have poorer survival rates and occur more 
often in patients with breast cancer 1 gene (BRCA1) mutations, although the link 
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between triple-negative/basal-like subsets and BRCA1 repair mechanisms is not 
clear (45,48). Tumors that retain ER, PR, and/or HER2 expression can be treated 
with combinatorial hormone and trastuzumab (Herceptin) therapies with relative 
success. Unfortunately, triple-negative/basal-like breast cancers are not 
responsive to these treatments and other targeted treatment strategies are limited. 
Current options include surgery, radiation, and chemotherapy with potential 
therapeutic candidates including anti-angiogenic agents, platinum salts, and poly 
ADP ribose polymerase inhibitors (48). However, once a triple-negative/basal-like 
breast cancer has metastasized, relapse is prevalent with very poor prognosis 
(50). 
The Hippo Pathway 
Overview and pathway members 
The Hippo pathway was originally discovered through forward genetic 
screens in Drosophila melanogaster that were investigating mediators of tissue 
overgrowth (51,52). These studies defined the Hippo pathway as a suppressor of 
tissue overgrowth primarily through the control of cell proliferation and apoptosis 
(53-58). Disruption of the upstream pathway components in flies leads to enlarged 
organs without major changes in overall patterning. Since these initial studies, the 
Hippo pathway and downstream effectors have been examined in the context of 
mammalian development and disease. It is clear that Hippo pathway components 
have critical roles in stem cell maintenance and differentiation as well as cancer. 
The focus of my thesis research was to investigate the roles of YAP/TAZ, the 
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primary effectors of the Hippo pathway in mammals, in the context of epithelial 
tumorigenesis and progression. 
The core Hippo pathway consists of a conserved kinase cascade that 
results in the phosphorylation and inhibition of two homologous transcriptional co-
regulators YAP and TAZ (also known as WW domain containing transcription 
regulator 1 or WWTR1) (YAP/TAZ; Drosophila Yorkie/Yki) (Figure 1.3). Upstream 
regulation is established through the phosphorylation and activation of sterile 20 
(STE20) kinases mammalian ste20-like serine/threonine 1 and 2 (MST1/2, 
Drosophila Hippo/Hpo) through unknown mechanisms. With the help of adapter 
proteins salvador (SAV2, Drosophila Sav) and mps one binder protein kinase like 
1 A/B (MOBKL1A/B, Drosophila Mats), MST1/2 phosphorylates and activates the 
nuclear dbf2-related (NDR) family kinases large tumor suppressor 1 and 2 
(LATS1/2; Drosophila Warts/Wts) (59,60). LATS1/2 in turn phosphorylates 
YAP/TAZ on several key serine residues to promote YAP/TAZ cytoplasmic 
localization and degradation (Figure 1.3). One mechanism contributing to the 
sequestration of YAP/TAZ is the binding of cytoplasmic 14-3-3 proteins, an 
interaction that is mediated by the phosphorylation of a specific serine residue 
(Ser127 in human YAP, Ser89 in human TAZ) (61,62). Another is the recruitment 
of ubiquitin ligases β-transducin repeat-containing protein/skp1/cul1/f-box complex 
(β-TrCP/SCF) to promote YAP/TAZ proteasomal degradation. This is mediated by 
LATS1/2 phosphorylation (Ser397 in YAP, Ser311 in TAZ), which promotes further 
phosphorylation events by casein kinase 1 ε/δ (CK1ε/δ; Ser400/403 in YAP, 
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Figure 1.3 - Regulation of YAP/TAZ localization. YAP/TAZ localization can be 
controlled through a variety of cellular cues. MST1/2 and LATS1/2 comprise the 
canonical Hippo pathway kinase cascade but other mechanisms are known to 
affect YAP/TAZ phosphorylation status both positively and negatively. 
Phosphorylated YAP/TAZ results in either their cytoplasmic retention or 
proteasomal degradation while unphosphorylated YAP/TAZ can accumulate in the 
nucleus and bind to a range of transcription factors, including the TEAD family. 
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Ser314 in TAZ) that are recognized by β-TrCP/SCF (63,64). β-TrCP recruitment 
can also be mediated by glycogen synthase kinase 3β (GSK3β) phosphorylation 
of TAZ (Ser58 and Ser62) (65). Alanine substitutions of LATS-targeted serine 
residues within YAP or TAZ promote their stability and nuclear localization. Once 
nuclear, YAP/TAZ are able to bind and direct the activity of many different 
transcription factors, including the TEAD family (TEAD1-4 also known as 
transcriptional enhancer factors or TEFs, Drosophila Scalloped/Sd) (Figure 1.3) 
(1). Together with YAP/TAZ, TEADs promote cellular transformation through the 
expression of cell proliferation and anti-apoptotic genes (66,67). Thus overall, 
active Hippo pathway signaling leads to decreased YAP/TAZ nuclear localization 
whereas inhibition of upstream components results in nuclear YAP/TAZ and 
increased transcriptional activity through the association with a range of 
transcription factors. 
Upstream regulation of the Hippo pathway 
The regulation of Hippo pathway activity is complex and may differ 
depending on tissue context. Various cues affect Hippo signaling to control 
YAP/TAZ localization including mechanical and soluble signals (Figure 1.3). 
Cytoskeletal dynamics and cell contacts are the best described but their 
dependence on upstream kinase signaling remains unclear. A striking observation 
has been made regarding the dynamic nature of YAP/TAZ localization during cell 
compaction. Sub-confluent cells display nuclear pools that shift to the cytoplasm 
upon high density (68). These signals are relayed in part through the establishment 
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of cell contacts and polarity complexes, which may function through both the 
sequestration and/or phosphorylation of YAP/TAZ. Many different proteins have 
been implicated in this process including cytoskeletal proteins Merlin and Frmd6, 
adherens junction protein alpha-catenin, tight junction protein ZO-2, polarity 
proteins of the Crumbs complex (PatJ, Mpdz, Pals1, Lin7c, Amot), and Scribble 
complex (Scrib, Dlg, Lgl) and the regulation is complex (69). To highlight, loss of 
alpha-catenin or either Crumbs or Scribble results in nuclear YAP/TAZ 
accumulation (12,70-72). The matrix surface area and stiffness that adherent cells 
interact with can also affect YAP/TAZ localization, probably through actin 
cytoskeleton dynamics and reorganization. For instance, stress fiber formation 
results in nuclear YAP/TAZ, which is dependent on the activity of Rho-GTPases 
and downstream Rho-kinases (73). Secreted factors can also modulate YAP/TAZ 
activity through g protein coupled receptor (GPCR) signaling. Phospholipids such 
as lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) signal through 
Gα12/13 and can promote nuclear YAP/TAZ activity. Conversely, hormones such 
as epinephrine and glucagon signal to inhibit YAP/TAZ nuclear activity. It is unclear 
how involved upstream Hippo pathway components are as LPA and hormone 
signaling appear to depend on LATS1/2-mediated phosphorylation of YAP/TAZ 
but are dispensable for S1P signaling (74,75). 
Role and regulation of transcriptional co-factors YAP and TAZ 
YAP and TAZ are structurally very similar and have approximately 60% 
sequence similarity in humans. Redundant functions exist for YAP and TAZ, 
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although they also seem to have independent roles in different tissue contexts, 
which may be explained through their structural domains and specificity of 
interacting partners (Figure 1.4) (69). The first identified domain of YAP/TAZ was 
the WW motif, consisting of two tryptophans that are 20-23 residues apart and are 
known to bind PPxY (proline-proline-amino acid-tyrosine) containing proteins. 
Several binding partners of YAP/TAZ have PPxY domains, most notably LATS1/2. 
Alternatively spliced isoforms of YAP and TAZ exist with either one or two WW 
domains, named YAP1-1 or YAP1-2 and TAZ1 or TAZ2 respectively, that may 
allow for differences in binding affinity to PPxY proteins (76-78). Interestingly, 
YAP1-1 and YAP1-2 interact differently with specific proteins, as YAP1-1 cannot 
bind p73 or angiomotin while YAP1-2 can (79,80). In addition, YAP1-2 appears to 
be the major isoform both in terms of expression and transcriptional activity, 
however only TAZ1 has been identified in humans (81,82). Both YAP and TAZ 
also have an unstructured transcriptional activation domain in their C-terminal 
region that is required for their transcriptional activity (83,84). The last four amino 
acids make up a PDZ-binding motif mediating binding to PDZ domain-containing 
proteins that can alter YAP/TAZ localization (85,86). 
YAP and TAZ cannot bind DNA directly and thus rely on transcription factors 
to relay their signals. They are known to bind many different transcription factors 
and are capable of stimulating or inhibiting the activity of these factors, although 
specific mechanisms are not well understood (69). YAP/TAZ interactions with 
TEADs are the best described, particularly in the context of tumorigenesis, and the  
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Figure 1.4 - YAP/TAZ protein domains. YAP and TAZ homologues share several 
important protein motifs. Most notably are the TEAD binding, WW, and 
transcriptional activation domains (TAD). YAP1-2 and TAZ1 isoforms are depicted, 
indicating the number of WW domains present. Specific serine residues and their 
known function are also highlighted. 
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oncogenic potential of YAP/TAZ relies on TEAD binding (67,87). This binding is 
mediated through a TEAD binding domain in the N-terminus of YAP/TAZ and can 
be disrupted by a single point mutation (Ser94 in YAP, Ser51 in TAZ) (67,87,88). 
Recently, phosphorylation by AMP-mediated protein kinase (AMPK) on this 
residue in YAP has been found to disrupt YAP-TEAD binding, suppressing cell 
proliferation and oncogenic transformation under low energy conditions (89). 
AMPK can also indirectly inhibit YAP by activating LATS to further restrict nuclear 
activity. Thus, AMPK links cellular energy stress to the Hippo pathway and is 
another point of regulation. 
YAP/TAZ in cancer 
Dysregulated YAP/TAZ activity is associated with a range of aggressive 
cancers and high nuclear levels correlate with high histological grade, increased 
invasiveness, and decreased survival rates in several cancers, including oral and 
breast cancers (12,90-95). Elevated YAP/TAZ also promote resistance to cancer 
therapies such as cisplatin and cetuximab, used to target OSCC, and paclitaxel 
and doxorubicin, used in breast cancer treatment (96-99). Initial studies of 
YAP/TAZ found that their increased nuclear activity potently drives cell 
transformation and tumor initiation through the control of proliferation, survival, and 
migration (100-102). This oncogenic activity is also associated with the acquisition 
of an EMT phenotype, which may explain the induced CSC properties that high 
expression of YAP/TAZ can confer (10,12). Transcriptional analysis of high-grade 
metastatic breast cancers revealed an enrichment of YAP/TAZ target gene 
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expression. Consistent with this observation, TAZ is required to maintain 
metastatic and CSC properties in breast cancer and expression of a nuclear TAZ 
mutant (TAZ-S89A) is sufficient to confer self-renewal of breast cancer 
populations. Whether YAP functions in the same capacity in this context is unclear 
and breast cancer tissue analysis has revealed that YAP levels change less 
dramatically than TAZ upon metastatic conversion, implying a more minor role for 
YAP in these cancer populations (12,101). 
YAP/TAZ have been hypothesized to function downstream of other 
transcriptional regulators known to promote CSC properties (12). Such factors 
include the transcriptional repressors Snail and Twist, which promote EMT and 
CSC properties by down-regulating genes important for cell polarity and adhesion 
(11,103). The proper organization of cell polarity complexes, such as Crumbs and 
Scribble, induce YAP/TAZ cytoplasmic localization and decreased transcriptional 
activity through their sequestration and phosphorylation. Scribble depletion or 
mislocalization induces tumorigenesis in breast cancers, perhaps through the 
deregulation of YAP/TAZ activity (104). Snail and Twist may be exerting partial 
effects indirectly through the modulation of YAP/TAZ. Consistent with this 
interpretation, TAZ knockdown inhibits CSC properties associated with Snail or 
Twist expression in breast cancer cells without affecting the disruption of polarity 
(12). Thus, YAP/TAZ are a prominent thread linking loss of polarity, induction of 
EMT, and CSC properties, and the combination of invasive properties with the 
ability to self-renew is suggested to drive aggressive cancers. 
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Although there is evidence that YAP is amplified in certain cancers, 
mutations in Hippo pathway components are not common (90,105,106). This 
suggests that dysregulation of YAP/TAZ activity occurs primarily on the level of 
protein expression and stability through the control of subcellular localization and 
phosphorylation. Interestingly, another manner of regulation may occur through 
YAP/TAZ expression as hypermethylation of CpG islands in the TAZ promoter 
correlate with reduced TAZ levels and lower-grade glioblastomas (107). 
Crosstalk with other pathways 
There is evidence that YAP/TAZ cooperate with other oncogenic signals to 
promote tumorigenesis and several other pathways frequently altered in cancer 
have been linked to Hippo signaling including signals regulated by MAPK, ERBB4, 
GPCRs, WNT, and TGFβ, among others (69,90,108,109). 
Recently, YAP has been linked to aberrant KRAS signaling in colon, lung, 
and pancreatic cancers and is necessary for KRAS-induced EMT through the 
activation of the FOS transcription factor (110). YAP was also shown to act 
downstream of KRAS-activated MAPK signaling to mediate the expression of pro-
tumorigenic secreted factors such as connective tissue growth factor (CTGF), 
cysteine-rich angiogenic inducer 61 (CYR61), and matrix metalloproteinase 7 
(MMP7) (111). RAS downstream of EGFR stabilizes YAP through the inhibition of 
suppressor of cytokine signaling 5/6. Stabilized YAP can promote the transcription 
of amphiregulin to create a positive feedback loop on EGFR signaling (112). 
  19 
Another member of the EGFR family often dysregulated in cancer, ERBB4, 
has been implicated in the regulation of YAP (113). Activation of transmembrane 
ERBB4 by extracellular neuregulin 1 ligand can result in proteolytic cleavage and 
release of an intracellular domain of ERBB4 (ICD ERBB4). ICD ERBB4 
translocates to the nucleus and binds YAP via PPxY-WW domain interactions to 
promote CTGF transcription and protumorigenic phenotypes (81,114). In this way, 
ERBB4 can act as an upstream receptor of the Hippo pathway and positively 
regulate YAP activity. 
GPCRs have also been described as upstream regulators of YAP and are 
often mutated in cancers (115). LPA, a GPCR activator, is also carcinogenic, 
perhaps through YAP signaling (116). Cancer associated mutations in Gαq and 
Gα11 can activate YAP in uveal melanoma, although it is unclear if this is mediated 
through LATS inactivation or is independent of upstream Hippo signaling 
(117,118). In either case, YAP is necessary for tumorigenic GPCR-induced 
signals, which can be blocked with verteporfin treatment, a small molecule inhibitor 
of YAP-TEAD binding (119). 
YAP and TAZ are known to interact with components of the wingless-related 
integration site (WNT) pathway to control signaling during development (69). 
Cytoplasmic YAP/TAZ function as an inhibitor of WNT signaling by suppressing 
the phosphorylation of the WNT pathway effector dishevelled 2 and by 
incorporating into the destruction complex to promote the degradation of β-catenin 
(120). In the presence of WNT, the destruction complex is relocated to the plasma 
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membrane and inactivated, freeing YAP/TAZ and β-catenin and allowing them to 
translocate to the nucleus where they can direct target gene transcription. The 
relationship between YAP/TAZ and WNT signaling is still incomplete and may be 
context dependent, which warrants further investigation (120-122). In colorectal 
cancers, loss of function of adenomatous polyposis coli or activating mutations in 
β-catenin are common and lead to unrestrained WNT signaling (123). In this 
context, active β-catenin can hyperactivate YAP by either physically interacting 
and promoting nuclear accumulation or driving YAP expression (124,125). 
In addition to WNT pathway components, YAP and TAZ are also known to 
interact with TGFβ-activated SMADs (70,126). TAZ can bind SMAD2/3-4 
complexes to direct their cellular localization and activity during development and 
YAP/TAZ-TEAD-SMAD2/3 complexes control transcriptional events necessary in 
the maintenance of human embryonic stem cell pluripotency (126,127). Disruption 
of polarity complexes in mammary epithelial cells, which promotes nuclear 
YAP/TAZ activity, also enhances TGFβ-induced SMAD nuclear responses through 
YAP/TAZ (70). YAP and TGFβ were found to function synergistically on specific 
gene targets in malignant mesothelioma. Specifically, YAP, TEAD4, SMAD3, and 
p300 form a complex that binds upstream of CTGF to stimulate gene expression 
(128). CTGF was previously identified as a direct gene target of both YAP and 
TGFβ in independent studies (67,129). CTGF is a secreted factor with known roles 
in promoting cell proliferation and EMT, however it is not completely clear how it 
exerts these effects. 
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The TGFβ pathway 
TGFβ signaling 
The TGFβ superfamily of secreted growth factors, encompassing over 40 
ligands including the prototypic TGFβ, Bone morphogenetic proteins, Activins, and 
Nodal, regulates numerous developmental, homeostatic, and tumorigenic 
processes (130-132). Three mammalian isoforms of TGFβ (TGFβ1, 2, and 3) are 
known, which function through the same downstream signaling pathway, although 
TGFβ1 is the most frequently expressed in cancer (133-135). Canonical TGFβ 
signals are transduced through SMAD proteins to control target genes such as 
regulators of cell proliferation, apoptosis, and matrix synthesis (Figure 1.5) (136). 
Latent TGFβ ligand is activated, through proteolytic cleavage, integrin binding, or 
mechanical stress, to promote dimer formation and binding to transmembrane 
serine/threonine kinase receptors, TGFβ receptor type I (TGFβRI) and type II 
(TGFβRII) (137). Once in contact with TGFβ ligand, TGFβRII recruits TGFβRI to 
form heteromeric complexes that result in the phosphorylation and activation of 
TGFβRI. Receptor activation transduces intracellular signaling through the 
phosphorylation of receptor-activated SMADs, SMAD2 and SMAD3 (SMAD2/3). 
Phosphorylated SMAD2/3 trimerize with SMAD4 and translocate to the nucleus 
where the complex binds SMAD binding elements to function as a transcriptional 
mediator (138-141). SMAD complexes bind with poor affinity to DNA and thus 
cooperate with other transcription factors to initiate chromatin remodeling that 
either activates or represses transcription depending on context (136,142). 
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Figure 1.5 - TGFβ signaling. TGFβ ligand binding to type I and type II TGFβ 
receptors results in SMAD phosphorylation and complex formation. Activated 
SMADs are able to translocate to the nucleus and control target gene transcription. 
Small molecule SB-431542 inhibits receptor phosphorylation and blocks SMAD 
activation. 
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TGFβ signals can be controlled through feedback signals regulated by 
target genes that encode negative regulators such as SMAD7 (143). SMAD7 can 
function in several different ways to inhibit TGFβ signaling through TGFβRI 
including directly blocking receptor phosphorylation and activation of receptor 
SMADs, recruiting protein phosphatase 1 to the receptor, or recruiting Smurf1/2 
ubiquitin ligases to target the receptor for proteasomal degradation (136,144,145). 
TGFβ in cancer 
TGFβ is known to play a major role during tumorigenesis and cancer 
progression. Various cells in the tumor microenvironment can be responsible for 
TGFβ production including the cancer cells and the stroma (146). It is also 
accepted that the effects of TGFβ are context dependent, as TGFβ suppresses 
growth in normal epithelial cells and early tumors but can promote proliferation and 
invasion in late stage tumors leading to more aggressive cancers (Figure 1.6) 
(146,147). The mechanism responsible for the switch in TGFβ activity has not been 
well defined although it is clear the loss of TGFβ suppressive effects combined 
with the acquisition of invasive properties is important during the process. 
In normal epithelial cells, TGFβ regulates cytostatic events primarily through 
the transcriptional regulation of genes involved in the G1/S phase restriction 
checkpoint, a crucial and evolutionarily maintained transition period that controls 
both cell division and genomic maintenance (148). For instance, TGFβ induces the 
expression of cyclin dependent kinase (CDK) inhibitors p15, p21, and p27 (149-
151). These proteins block G1/S phase cyclins from associating with their  
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Figure 1.6 - Dual roles for TGFβ in tumorigenesis. TGFβ is known to exert 
different cellular effects depending on tissue context. In normal tissue and early 
stage tumors, TGFβ suppresses tumorigenesis by inducing cytostasis and 
apoptosis. However, in more advanced cancers, TGFβ activity switches to 
promote cell invasion and survival. 
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respective kinases, predominantly cyclin D-CDK4/6 and cyclin E-CDK2, 
preventing retinoblastoma (Rb) protein phosphorylation and entry into S phase 
(148). TGFβ also suppresses the expression of proliferative factors such as the 
transcription factor c-Myc and the inhibitor of DNA-binding family, which can inhibit 
Rb activity allowing for cell cycle progression (152-155). In late stage tumors, 
mutations in p15 develop and the suppression of c-Myc or inhibitor of DNA-binding 
family gene targets is lost, leading to disruption of TGFβ mediated cytostasis (156-
159).  
TGFβ signaling can direct apoptotic events through both transcriptional and 
spatial regulation of various apoptotic factors. Several diverse pro-apoptotic genes 
are transcriptional targets of TGFβ including TGFβ-inducible early response gene 
transcription factor, death-associated protein kinase, and sh2-domain containing 
inositol-5-phosphatase, an inhibitor of AKT signaling (160-162). Other factors can 
directly relay TGFβ cues to modulate apoptosis like Apoptosis-related protein in 
the TGFβ signaling pathway, which moves from the mitochondria to the nucleus 
upon TGFβ stimulation to suppress inhibitors of apoptosis, or the adapter protein 
death domain-associated protein 6, which promotes JNK activation through its 
association with TGFβRII (163,164). 
TGFβ promotes EMT through the regulation of Snail, Slug, and Twist 
transcription factors and the suppression of epithelial markers like E-cadherin 
(165). This is a key process in development, particularly during gastrulation, and 
requires properly coordinated steps that become uncontrolled in cancer (166). In 
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breast cancer, TGFβ confers CSC properties through the induction of EMT 
resulting in the expansion of CD44high/CD24low populations (11,167). Treatment 
with a TGFβRI kinase blocker induces these cells to adopt a more epithelial 
phenotype (167). 
TGFβ plays additional roles in the tumor microenvironment besides 
regulating cell growth and invasion in cancer cells. Originally, TGFβ was 
discovered to enhance the proliferation of fibroblasts and is known to activate 
fibroblasts to induce extracellular matrix (ECM) remodeling (168,169). In the 
microenvironment, TGFβ can stimulate CAFs to secrete factors that modify the 
extracellular matrix, promote proliferation, invasion, and angiogenesis, which can 
signal to the cancer cells (170-172). Again, the source of TGFβ can come from 
several populations within the tumor including both the CAFs and cancer cells, 
allowing for intercellular communication and the potential for the generation of a 
feed-forward loop to promote aggressive cancers (146,173).  
Significance and research goals 
Deregulated Hippo pathway signaling promotes the onset of aggressive 
cancers (59). Through the work of several laboratories, the Hippo pathway has 
emerged as a central signal transduction pathway that integrates mechanical and 
extracellular cues to control cell proliferation, apoptosis, and cell fate 
(120,126,174,175). The localization and activity of the transcriptional regulators 
YAP/TAZ mediates Hippo pathway signaling responses, and uncontrolled nuclear 
YAP/TAZ activity evokes cell proliferation, tumor-initiating properties, and drug-
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resistance in a broad range of cancers (1,174). While YAP/TAZ are essential for 
accurate organ growth, a gap in knowledge exists for how YAP/TAZ direct 
transcription to promote tumor-initiation and how they interact with other signaling 
pathways to accomplish this. Insight into these molecular details is critical for 
understanding general mechanisms of tumor suppression and is necessary for the 
development of effective cancer therapeutics. 
The goal of this thesis research was to define the mechanisms mediating 
Hippo pathway-mediated tumorigenesis by 1) exploring the roles of YAP/TAZ in 
the formation and progression of oral cancer and 2) investigating how the 
convergence of YAP/TAZ and TGFβ-induced transcriptional cues promote 
tumorigenesis in breast cancer. I hypothesize that YAP/TAZ drive pro-tumorigenic 
events in oral cancer and cooperate with TGFβ signals to promote aggressive 
breast cancers. 
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CHAPTER II - MATERIALS AND METHODS 
Cell culture and transfections 
CAL27, Squamous cell carcinoma 2 (SCC2), Breast tumor 20 (BT20), 
HS578T, SKBR3 and HEK293T cells were cultured in DMEM (Hyclone) 
supplemented with 10% FBS (Hyclone) and 1% penicillin/streptomycin (P/S) 
(Gibco, Life Technologies). SCC9, SCC15 and SCC25 cells were cultured in 
DMEM/F12 (1:1) (Hyclone) supplemented with 10% FBS, 400 ng/mL 
hydrocortisone (Sigma) and 1% P/S. Michigan cancer foundation 10A and 12A 
(MCF10A and MCF12A) cells were cultured in DMEM/F12 (1:1) supplemented with 
5% horse serum (HS) (Gibco, Life Technologies), 20 ng/mL EGF (PeproTech), 500 
ng/mL hydrocortisone, 100 ng/mL cholera toxin (Sigma), 10 μg/mL insulin (Sigma), 
and 1% P/S. Human mammary epithelial (HMLE) cells were cultured in DMEM/F12 
(1:1) supplemented with 20 ng/mL EGF, 500 ng/mL hydrocortisone, 100 ng/mL 
cholera toxin, 10 μg/mL insulin, and 1% P/S. MCF7 cells were cultured in DMEM 
supplemented with 10% FBS, 10 μg/mL insulin, and 1% P/S. MDA-MB-231 and 
LM2-4 cells were cultured in Roswell park memorial institute media 1640 (RPMI 
1640) (Gibco, Life Technologies) supplemented with 10% FBS and 1% P/S. 
SUM149 cells were cultured in Ham’s F12 (Hyclone) supplemented with 5% HS, 
400 ng/mL hydrocortisone, and 10 μg/mL insulin. Cell lines and culture conditions 
are outlined in Table 1. 
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Table 1 - Cell lines and culture conditions 
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For transfections, RNA interference was performed by transfecting siRNA 
using Dharmafect 1 (Thermo Scientific) according to manufacturer’s protocol. 
siRNA sequences are outlined in Table 2. HEK293T cells were transfected using 
TurboFect (Thermo Scientific) according to manufacturer’s protocol. Prior to 
transfection, HEK293T cells were plated on dishes coated with 1% poly-L-lysine 
for 30 minutes at 37°C. 
Lentivirus production and stable cell lines 
HEK293T cells were co-transfected with 1.5 μg/μL of ps paired box gene 2, 
0.75 μg/μL of pCMV-vesicular stomatitis virus G protein, and 1.5 μg/μL of each 
viral plasmid. Media was changed the following day to DMEM supplemented with 
10% heat inactivated FBS and cells were incubated an additional 2-3 days to 
produce virus. Media was collected and filtered using 0.45 μm filters. 100 μL of 
virus was used to infect sub-confluent cells and cells were selected 2-3 days after 
infection. 
CAL27 and MCF10A doxycycline-inducible stable cell lines were 
engineered using the lentiviral Tet-On system (Clontech). 3xFLAG-tagged mutants 
of YAP (5SA: S61A, S109A, S127A, S164A, S97A or 5SA/S94A) or TAZ (4SA: 
S66A, S89A, S117A, S311A) were generated by site-directed mutagenesis and 
cloned into the pLVX-Tight-Puro plasmid (#632162, Clontech). Tet-On cells were 
selected with G-418 sulfate (Gold Biotechnology) and pLVX-Tight-Puro cells were 
selected with puromycin (American Bioanalytical or Invivogen). Selection 
conditions are outlined in Table 1.  
  31 
Table 2 - siRNA and shRNA sequences 
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SCC2-dsRED fluorescent cells were generated using lentiviral transduction 
of CMV-promoter driven dsRED. Stable knockdown of YAP and TAZ in SCC2-
dsRED and LM2-4 cells was accomplished by lentiviral-mediated transduction of 
shRNA using the pLKO1-puro (a gift from Bob Weinberg (176)) and pLKO1-neo 
vectors (a gift from Sheila Stewart). pLKO1 vectors were engineered to express 
shRNA targeting control (shCTL), YAP (shYAP, pLKO1-shYAP-2 was a gift from 
Kun-Liang Guan, Addgene plasmid #27369 (67)), or TAZ (shTAZ (177)). Selection 
conditions are outlined in Table 1 and shRNA sequences are outlined in Table 2. 
Cell treatments 
Doxycycline-inducible cells were treated with doxycycline (0.1 to 100 ng/mL 
or 100 ng/mL if not otherwise stated, Clontech) for at least 24 hours to induce the 
expression of 3xFLAG-tagged YAP-5SA, 5SA/S94A, or TAZ-4SA. 
Cells were treated with TGFβ1 (500 pM, R&D) and/or SB-431542 (5 μM, 
Sigma) for 2 to 24 hours as indicated.  
Human oral tissue specimens 
Tissue specimens were obtained from patients at Boston University Medical 
Center, and were acquired from scalpel-generated incisional biopsies of oral 
epithelium (benign epithelial hyperplasia (n=7), mild (n=3) and severe (n=3) 
dysplasia), as well as from surgical resections of moderately differentiated (n=6) 
and poorly differentiated (n=4) OSCCs of the lateral tongue border and of the floor 
of the mouth. For each condition, cytologically normal adjacent epithelia were also 
obtained and analyzed. Benign epithelial hyperplasia, dysplasia, and OSCC 
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regions, as well as adjacent epithelia, were defined by an on-site histopathological 
examination by Vikki Noonan and tissues were snap-frozen at -80oC. A portion of 
these tissues were sectioned and used for H&E staining and immunofluorescence 
imaging or were lysed for biochemical analysis (see below). The institutional 
review board at the Boston University Medical Campus approved the use of human 
oral tissue specimens for these studies. 
Expression analysis of The Cancer Genome Atlas (TCGA) OSCC data 
Normalized Level 3 gene expression (RNASeqV2) and associated clinical 
data were obtained from TCGA corresponding to the Head and Neck Squamous 
Cell Carcinoma dataset (n=340; https://tcga-data.nci.nih.gov/tcga/). Samples were 
filtered so as to retain only those belonging to one of six oral cancer anatomic 
subtypes (Alveolar Ridge, Base of tongue, Buccal Mucosa, Floor of mouth, Oral 
cavity, Oral tongue), and only Caucasian patients were analyzed (filtered Oral 
Cancer dataset size: n=193). Box plots of the expression values were generated 
with respect to tumor grade/stage for YAP and TAZ (log2-transformed). 
Protein isolation and co-immunoprecipitation (co-IP) 
Cell monolayers were lysed in lysis buffer (50 mM Tris (pH 7.5), 150 mM 
sodium chloride (NaCl), 1 mM EDTA, 0.5% Triton X-100, and 1X Halt™ protease 
inhibitor cocktail (Thermo Scientific)) and were agitated for 10 minutes at 4°C. 
Human tissue samples were weighed and lysed in a relative amount of Triton X-
100/β-octylglucoside buffer (10 mM imidazole, 100 mM NaCl, 1 mM magnesium 
chloride, 5 mM sodium EDTA, 1% Triton X-100, 0.87 mg/mL β-octylglucoside, and 
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1X Halt™ protease inhibitor cocktail), as previously described (178). 
Approximately 100 μL of buffer was used per 0.1 mg of tissue. Homogenization 
was performed with the Bullet Blender® (Next Advance, Inc.) using 1 scoop of 0.5 
mm stainless steel beads per sample incubated on setting 9 for 4 minutes. Both 
cell and tissue lysates were cleared of debris by centrifuging at max speed at 4°C 
for 10 minutes. Supernatants were collected and samples were normalized using 
Pierce bicinchoninic acid protein assay kit (Thermo Scientific). Equal protein 
fractions were analyzed by SDS-PAGE gel followed by immunoblotting (see 
below). 
HEK293T cells were co-transfected with the following tagged constructs 
driven by the CMV promoter: HA-SMAD3 (0.5 μg), FLAG-TEAD4 (0.25 μg), FLAG-
TEAD2 (0.25 μg), MYC-YAP (0.5 μg) and His-TGFβR1-T240D (0.1 μg). Media was 
changed the following day and cells were incubated an additional 24 hours. Cells 
were lysed as cell monolayers (see above). Total fractions were removed from the 
lysate supernatant and the remaining fraction was used for co-IP. Co-Ips were 
performed using 20 μL anti-FLAG M2 affinity gel (Sigma) for 1 hour at 4°C. Beads 
were precipitated by centrifugation at 3000 RPM for 30 seconds and washed 5 
times with IP wash buffer (50 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA, 0.1% 
Triton X-100) and eluted in SDS-PAGE load buffer (0.1 M Tris (pH 6.8), 10% 
glycerol, 2% SDS, 0.01% Bromophenol blue, 100 mM DTT) for analysis by SDS-
PAGE gel followed by immunoblotting (see below) 
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Immunoblots 
SDS load buffer was added to equal protein fractions and samples were 
boiled at 95°C for 5 minutes. Samples were loaded and separated on freshly made 
10% SDS-PAGE gels (Resolving gel: 10% acrylamide, 375 mM Tris (pH 8.8), 0.1% 
SDS, 0.1% ammonium persulfate, 0.05% tetramethylethylenediamine; Stacking 
gel: 3.5% acrylamide, 250 mM Tris (pH 6.8), 0.1% SDS, 0.1% ammonium 
persulfate, 0.08% tetramethylethylenediamine) in SDS-PAGE running buffer (25 
mM Tris, 192 mM glycine, 0.1% SDS) at 220 V for 1 hour and 10 minutes. Proteins 
were immobilized on 0.45 μm nitrocellulose membranes (Bio-Rad Laboratories) by 
transferring in 1X transfer buffer (25 mM Tris, 200 mM glycine, 20% methanol) at 
100 V for 1.5 hours. Membranes were stained with Ponceau S for 5 minutes at 
room temperature if necessary and washed with water until bands were visible and 
background turned white. Images were captured to visualize total protein. 
Membranes were then blocked in either 5% nonfat dry milk (LabScientific, Inc.) or 
5% BSA (Fisher), depending on primary antibody protocol, diluted in TBS-T (20 
mM Tris, 150 mM NaCl, 0.1% Tween-20) for 30 minutes at room temperature. 
Membranes were incubated in primary antibody overnight at 4°C. The following 
day membranes were washed 3 times 10 minutes in TBS-T. Primary antibodies 
conjugated to horseradish peroxidase (HRP) were immediately visualized. 
Membranes in unconjugated primary antibodies were incubated in secondary 
antibody for 1 hour at room temperature, washed again 3 times 10 minutes in TBS-
T and immediately visualized. All blots were visualized using either Super Signal 
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West Dura Extended Substrate (Thermo Scientific) or Super Signal West Femto 
Maximum Sensitivity Substrate (Thermo Scientific), exposed for 1 to 240 seconds, 
and captured on Chemi Doc™ XRS+ imaging station (Bio-Rad Laboratories) using 
Image Lab software (Bio-Rad Laboratories). Expressed proteins were compared 
to BLUEstain 3 protein ladder (Gold Biotechnology) to determine size. All 
antibodies are outlined in Table 3. 
Immunofluorescence and Proximity Ligation Assay (PLA) 
Cells were plated on coverslips for immunofluorescence or on 96-well black-
walled, transparent-bottom microplates (BD Falcon) for PLA. Cells were washed 
one time with PBS (137 mM NaCl, 10 mM sodium phosphate (dibasic), 1.8 mM 
monopotassium phosphate (monobasic), 2.7 mM potassium chloride pH 7.4) and 
fixed in 4% paraformaldehyde-PBS for 15 minutes at room temperature. Cells were 
permeabilized with 0.1% Triton X-100-PBS for 10 minutes, blocked in 2% BSA-
PBS for 1 hour at room temperature. For the analysis of human samples, tissues 
were fixed and paraffin embedded. 3 μm sections were placed on OptiPlus 
Positive-Charged Barrier Slides (BioGenex), deparaffinized, treated with Retrievit-
6 Target Retrieval Solution (BioGenex), and blocked with 10% goat serum. 
Samples were incubated with primary antibodies overnight at 4°C. For cell and 
tissue immunofluorescence, cells were washed the following day 5 times in PBS-
T (PBS with 0.1% Tween-20) and incubated in fluorescently conjugated secondary 
antibodies for 1 hour at room temperature. After fluorescent antibodies were 
added, samples were protected from light for all remaining steps. For PLA, anti-
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Table 3 - Antibodies 
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mouse MINUS and anti-rabbit PLUS PLA probes (Duolink) were used and 
manufacturer’s protocol was followed for subsequent ligation and amplification 
steps. All samples were washed 5 additional times in PBS-T and counterstained 
with either Hoechst (diluted 1:10,000 for a final concentration of 1 μg/mL in PBS) 
for 15 minutes at room temperature or DAPI. Tissues analyzed in the absence of 
primary antibodies were used as negative controls. Coverslips were inverted and 
mounted on microscopy slides with Vectashield mounting media (Vector 
Laboratories) or Vectashield mounting media was added directly to each 
microplate well. Immunofluorescence and PLA were visualized by confocal 
microscopy (Zeiss laser scanning microscope 700 or Zeiss laser scanning 
microscope 510 Axiovert 200M) and images were processed using Volocity 
software (PerkinElmer). Images were quantitated using ImageJ software. All 
antibodies are outlined in Table 3. 
Cell proliferation and cell cycle analysis 
SCC2 cells were transfected with siRNA and cultured for 24 hours. Cells 
were then plated (5x104 cells) (Day 0) and counted by hemocytometer each day 
for 6 consecutive days (Day 1-6), with media changed every 2 days. CAL27 
doxycycline-inducible cells were pre-treated with doxycycline (100 ng/mL) for 24 
hours. Cells were plated (5x104 cells) (Day 0) in the presence of doxycycline. Cells 
were counted by hemocytometer every 2 days for 2 weeks (Day 2-14) and media 
was changed every 2 days. MCF10A doxycycline-inducible cells were plated 
(5x104 cells) and treated with doxycycline (100 ng/mL) with or without TGFβ1 (500 
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pM) (Day 0). Cells were counted by hemocytometer each day for 6 consecutive 
days (Day 1-6), with media changed every 2 days. All cell proliferation experiments 
were performed in triplicate and statistical analysis was conducted with Prism 
software (GraphPad) using a two-tailed unpaired Student’s t test. 
For cell cycle analysis, MCF10A doxycycline-inducible cells were treated 
with doxycycline (100 ng/mL) with or without TGFβ1 (500 pM) for 48 hours. 1x106 
cells were fixed overnight in 100% ethanol and stained with Propidium Iodide (50 
μg/mL, Sigma) and RNase A (100 μg/mL, Sigma). Samples were acquired on the 
FACScan (BD Biosciences), collecting 1x104 events, and analyzed using FlowJo 
software (Treestar). Experiment was performed in triplicate and statistical analysis 
was conducted with Prism software (GraphPad) using a two-tailed unpaired 
Student’s t test. 
Caspase 3/7 activity 
SCC2 cells were transfected with siRNA and cultured for 48 hours. CAL27 
doxycycline-inducible cells were treated with doxycycline (100 ng/mL) for 24 hours. 
Cleaved Caspase-3 and -7 activity was measured using the Caspase-Glo 3/7 kit 
(Promega) according to manufacturer’s protocol. Experiment was performed in 
triplicate and statistical analysis was conducted with Prism software (GraphPad) 
using a two-tailed unpaired Student’s t test. 
Wound healing and transwell migration 
For wound healing, SCC2 or LM2-4 cells were transfected with siRNA. After 
24 hours, media was changed and cells were treated with or without TGFβ1 (500 
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pM) or SB-431542 (5 μM) for an additional 24 hours. CAL27 and MCF10A 
doxycycline-inducible cells were treated with or without doxycycline (100 ng/mL) 
or TGFβ1 (500 pM) for 24 hours. Monolayers were wounded and photographed at 
0 hours and after an additional 12 to 24 hours. Images were captured and analyzed 
using ImageJ software. All wound healing experiments were performed in triplicate 
and statistical analysis was conducted using Prism software (GraphPad) with a 
two-tailed unpaired Student’s t test. 
For transwell migration, LM2-4 cells were transfected with siRNA. After 24 
hours, cells were trypsinized and resuspended in low serum media (0.25% FBS). 
Cells were plated in triplicate at 105 cells/mL on 8 μm transwell filters (BD 
BioSciences) coated for 24 hours with 1 μg/mL fibronectin (Millipore). Media 
supplemented with 10% FBS was used in the bottom chamber. Cells were allowed 
to migrate for 24 hours in the presence of TGFβ1 (500 pM) and were subsequently 
stained with 0.5% crystal violet. 
Tongue orthotopic mouse injections and in vivo imaging system (IVIS) 
imaging 
All experiments were approved by the Boston University Medical Center 
Institutional Animal Care and Use Committee. Two month old female nude mice 
(NCr nu/nu; Taconic Farms, Hudson, NY) were injected in the tongue with 3x105 
SCC2-dsRed shCTL, shYAP, or shY/T cells (n=9 mice per group) in respective 
groups after anesthetizing with 4% isoflurane. Primary tumors were directly 
measured with calipers on day 10, 15, 18, and 22 to obtain tumor volume. IVIS 
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imaging was performed on day 22 using the Caliper IVIS Spectrum Imaging 
System (Xenogen) to visualize fluorescence (570 nm excitation, 620 nm emission, 
exposed for 1.0 second). Regions of interest were quantitated for each mouse 
using Living Image software and background radiant efficiency in vehicle mice was 
subtracted. Statistical analysis was conducted with Prism software (GraphPad) 
using a two-tailed unpaired Student’s t test. 
Microarrays 
SCC2 cells were transfected with control siRNA, or siRNAs targeting TAZ, 
YAP, or YAP/TAZ. siRNA sequences are outlined in Table 2. After 48 hours, total 
RNA from three independent experiments carried out on separate days was 
isolated and purified by Rneasy Mini Kit (Qiagen), and the samples were then 
profiled on Affymetrix Human Gene 2.0 Chips at the Boston University Microarray 
Core. The microarray data are available at Gene Expression Omnibus (GEO); 
accession GSE66949. The expression profiles were processed and normalized 
using the Robust Multi-array Average procedure (179) based on a custom 
Brainarray Cumulative Distribution Function (180). For each of the siRNA 
experiments, signatures of genes differentially expressed between treatment and 
corresponding siRNA control with a false discovery rate (FDR) q-value ≤0.05 and 
a fold change ≥2 were identified as either activated (up-regulated in control) or 
repressed (up-regulated in treatment). The overlap between the differentially 
expressed gene signatures was evaluated by Fisher test. Hierarchical gene and 
sample clustering was performed on the top 3000 genes with highest median 
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absolute deviation (MAD; a robust version of the variance) across 12 samples, 
using “ward” as the agglomeration rule, and 1 minus Pearson correlation and 
Euclidean as the distance measures for genes and samples, respectively. 
LM2-4 cells were transfected with control siRNA, or siRNAs targeting 
YAP/TAZ or all four TEADs and were treated 24 hours later with TGFβ1 (500 pM) 
or SB-431542 (5 μM) for an additional 24 hours. siRNA sequences are outlined in 
Table 2. Total RNA was isolated and purified by Quick-RNA MiniPrep (Zymo 
Research). Twelve microarrays in total were performed, with each condition 
carried out three times on separate days. The Boston University Microarray Core 
generated the data using the Affymetrix Human Gene 1.0 St Array, which covers 
27,300 probesets. The microarray data are available at GEO; accession 
GSE56445. The data were filtered using a moderated p-value of less than 0.01, 
and the average fold change in expression of each gene, for each condition, 
relative to the siCTL+TGFβ sample was calculated. Fold-expression changes 
relative to siCTL+TGFβ treated cells were calculated, and statistical significance 
was assessed using a moderated t test and p-values. Hierarchical gene clustering 
was performed on overlapping genes displaying a p-value<0.01 with the open 
source program Cluster 3.0 (181). 
Hierarchical clustering of expression signatures and projection on tumor 
progression  
Normalized Level 3 gene expression (RNASeqV2) and associated clinical 
data obtained from TCGA filtered as described above to retain only samples of 
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Caucasian origin from one of the six oral cancer anatomic subtypes (Alveolar 
Ridge, Base of tongue, Buccal Mucosa, Floor of mouth, Oral cavity, Oral tongue; 
filtered Oral Cancer dataset size: n=193) were used for the hierarchical clustering 
analysis. Identified clusters were annotated by pathway enrichment based on a 
hyper-geometric test against the set of curated pathways (c2.cp) in the Molecular 
Signatures Database compendium (182). To test whether gene signatures defined 
by microarray experiments were up- or down- regulated with respect to tumor 
status or tumor grade/stage, GSEA analysis was performed to test whether the 
activated/repressed gene signatures were enriched in tumor versus normal or 
higher grade versus lower grade tumors (183).  
Hyperenrichment analysis  
To evaluate whether specific pathways or transcription factors might play a 
role in the response to targeted inhibition, enrichment analysis of the differential 
signatures based on a hyper-geometric test was performed. To this end, each of 
the up- and down-regulated signatures (with FDR≤0.05 and fold-change≥2) was 
tested against the Molecular Signatures Database c2.cp (canonical pathways), 
c3.all (TF/miR targets), and c6.all (oncogenic pathways) compendiums.  
Reverse transcription quantitative PCR (RT-qPCR) 
SCC2 or LM2-4 cells were transfected with siRNA. After 24 hours, media 
was changed and cells were treated with or without TGFβ1 (500 pM) or SB-431542 
(5 μM) for an additional 24 hours. CAL27 and MCF10A doxycycline-inducible cells 
were treated with or without doxycycline (100 ng/mL or 0.1 to 100 ng/mL, 
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respectively) or TGFβ1 (500 pM) for 24 hours. Total RNA was purified using 
Rneasy mini prep kit (Qiagen) and complementary DNA (cDNA) synthesis was 
performed using 1 μg RNA and iScript cDNA synthesis kit (Bio-Rad Laboratories) 
according to manufacturer’s protocol. Quantitative PCR (qPCR) was performed 
using Fast SYBR green enzyme (Applied Biosystems) and measured on ViiA 7 
real time PCR system (Applied Biosystems). Transcript levels were analyzed using 
ΔΔCT method and normalized to GAPDH. Primer sequences are outlined in Table 
4. All experiments were performed in triplicate and statistical analysis was 
conducted with Prism software (GraphPad) using a two-tailed unpaired Student’s 
t test. 
Flow cytometry 
MCF10A, MDA-MB-231, and LM2-4 cells were dissociated, washed, and 
counted. Cells were resuspended at 106 cells/100 μL and probed with FITC-CD44 
and phycoerythrin (PE)-CD24 per manufacturer’s protocol, as previously 
described (184). Antibodies are outlined in Table 3. Briefly, cells were protected 
from light and incubated at 4 C for 30 minutes. Cells were washed and fixed in 
1% paraformaldehyde in PBS. After fixation, cells were filtered through 40 μm 
strainers (BD Biosciences) and analyzed on a FACScan (BD Biosciences). 
Mammospheres 
LM2-4 cells were transfected with siRNA, dissociated 24 hours later, and 
resuspended in Mammary Epithelium Growth Medium (MEGM; Lonza) 
supplemented with B27 (Invitrogen), 20 ng/mL EGF, 20 ng/mL basic fibroblast  
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Table 4 - Primer sequences 
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growth factor (FGF2; Peprotech), and 1% P/S. Single cells were seeded at 5x103 
cells/mL in 6-well ultra-low attachment plates (Corning) and treated with or without 
TGFβ1 (500 pM) or SB-431542 (5 μM). Primary spheres were photographed after 
7 days and either lysed for RNA by Quick-RNA MiniPrep kit to examine knockdown 
or dissociated in 0.05% trypsin for 10 minutes and resuspended as single cells in 
MEGM media for passage. Secondary spheres were photographed after an 
additional 14 days. Images were analyzed using ImageJ software and statistics 
were calculated using Prism software (GraphPad) using a two-tailed unpaired 
Student’s t test. 
Three-dimensional invasion 
LM2-4 cells with stable shRNA knockdown (see above) were plated as 
single cells on 100% growth factor-reduced Matrigel (BD Biosciences) using the 
overlay method (185). Assay media contained 2% Matrigel added to supplemented 
MEGM media, and cells were cultured with puromycin and G-418 selection (see 
Table 1) with media changed every 3 days. TGFβ1 (500 pM) and SB-431542 (5 
μM) were added after 9 days, and cells were cultured for an additional 3 days 
before being photographed. 
Chromatin immunoprecipitation (ChIP) 
LM2-4 cells were fixed in triplicate with ethylene glycol bis (succinimidyl 
succinate) (1 mM, Thermo Scientific) for 30 minutes, 1% formaldehyde for 10 
minutes, and quenched in 0.125 M glycine in PBS. Cells were collected and lysed 
in Cell Lysis buffer (10 mM potassium hydroxide/HEPES pH 7.8, 85 mM potassium 
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chloride, 1 mM EDTA pH 8.0, 1% NP-40) with 1X Halt™ protease inhibitor cocktail 
(Thermo Scientific). Nuclei were lysed in Nuclear Lysis buffer (50 mM Tris pH 7.4, 
1% SDS, 10 mM EDTA pH 8.0) with 1X Halt™ protease inhibitor cocktail, and 
genomic DNA was fragmented to <400 bp using Bioruptor bath sonicator 
(Diagenode) 3 times for 15 minutes each, in 15 cycles of 30 seconds on 30 
seconds off. Immunoprecipitations (Ips) were performed overnight using 
antibodies outlined in Table 3 (Note: anti-TEAD4 also recognizes TEAD1 and 3 
(127)) followed by incubation with protein-G Dynabeads (Invitrogen) for 1 hour at 
4°C. Immunoprecipitated complexes were washed sequentially 2 times each in the 
following buffers: Wash buffer A (20 mM Tris pH 7.6, 140 mM NaCl, 1 mM EDTA 
pH 8.0, 0.1% sodium deoxycholate (NaDeoxycholate), 0.1% SDS, 1% Triton X-
100), Wash buffer B (20 mM Tris pH 7.6, 500 mM NaCl, 1 mM EDTA pH 8.0, 0.5% 
NaDeoxycholate, 1% Triton X-100), Wash buffer C (20 mM Tris pH 7.6, 1 mM 
EDTA pH 8.0, 0.5% NaDeoxycholate, 1% Triton X-100, 250 mM lithium chloride), 
and TBS (20 mM Tris pH 7.6, 50 mM NaCl, 1 mM EDTA pH 8.0). Samples were 
eluted in Elution buffer (50 mM sodium bicarbonate, 50 mM Tris pH 8.0, 2 mM 
EDTA pH 8.0, 1% SDS). Cross-links were reversed overnight at 65C in 0.2 M 
NaCl in Elution buffer and DNA was purified using QIAquick PCR purification 
columns (Qiagen) and eluted in 50 μL deionized distilled water. Samples were 
analyzed by qPCR in duplicate using 2 μL of eluted IP or 2 μL 0.5% input per qPCR 
reaction and data were analyzed using the percent-input method. Primers were 
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designed based on putative TEAD sequences found in nearby upstream promoter 
regions and are outlined in Table 4. 
Cell morphology analysis 
Low-density MCF10A doxycycline-inducible cells were pre-treated with 
doxycycline (100 ng/mL) for 24 hours, then treated with or without TGFβ1 (500 
pM) for an additional 24 hours before being photographed. 
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CHAPTER III - A YAP/TAZ-REGULATED MOLECULAR SIGNATURE IS 
ASSOCIATED WITH ORAL SQUAMOUS CELL CARCINOMA 
Disclaimer: This chapter is adapted from Hiemer, S. E., Zhang, L., Kartha, V. K., 
Packer, T. S., Almershed, M., Noonan, V., Kukuruzinska, M., Bais, M. V., Monti, 
S., and Varelas, X. (2015) A YAP/TAZ-Regulated Molecular Signature Is 
Associated with Oral Squamous Cell Carcinoma. Molecular Cancer Research 13, 
957-968 (186). 
Abstract 
Oral squamous cell carcinoma (OSCC) is a prevalent form of cancer that 
develops from the epithelium of the oral cavity. OSCC is on the rise worldwide, 
and death rates associated with the disease are particularly high. Despite progress 
in understanding of the mutational and expression landscape associated with 
OSCC, advances in deciphering these alterations for the development of 
therapeutic strategies have been limited. Further insight into the molecular cues 
that contribute to OSCC is therefore required. In this chapter, I show that the 
transcriptional regulators YAP and TAZ, which are key effectors of the Hippo 
pathway, drive pro-tumorigenic signals in OSCC. Regions of pre-malignant oral 
tissues exhibit aberrant nuclear YAP accumulation, suggesting that dysregulated 
YAP activity contributes to the onset of OSCC. Supporting this premise, I 
determined that nuclear YAP and TAZ activity drives OSCC cell proliferation, 
survival, and migration in vitro, and is required for OSCC tumor growth and 
metastasis in vivo. Global gene expression profiles associated with YAP and TAZ 
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knockdown revealed changes in the control of gene expression implicated in pro-
tumorigenic signaling, including those required for cell cycle progression and 
survival. Notably, the transcriptional signature regulated by YAP and TAZ 
significantly correlates with gene expression changes occurring in human OSCCs 
identified by "The Cancer Genome Atlas" (TCGA), emphasizing a central role for 
YAP and TAZ in OSCC biology.  
Introduction 
Oral squamous cell carcinoma (OSCC) originates from the epithelium of the 
oral cavity and represents the majority of head and neck cancers. Very poor 
survival rates are associated with those afflicted by OSCC (only ~50% survival 
over five-years), and unfortunately little progress has been made with treatment 
strategies over the past few decades (35). Therefore, understanding dysregulated 
molecular cues associated with OSCC onset and progression is an important step 
in the development of effective therapeutics.  
Recent studies have shown that aberrant activation of the transcriptional 
regulators YAP and TAZ (YAP/TAZ) contributes to the onset and progression of a 
range of cancers (90). YAP/TAZ transcriptional activity is dependent on their 
recruitment to the nucleus, which promotes binding to a range of transcription 
factors, most notably the TEAD family (67,187). YAP/TAZ-directed transcription 
promotes cell proliferation, pro-survival, and cell migration signals, all of which 
contribute to the pro-tumorigenic roles of YAP/TAZ (100-102). Multiple signaling 
events restrict YAP/TAZ from the nucleus, the best characterized of which are 
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signals mediated by the Hippo pathway (69). In particular, Hippo pathway 
activation promotes the phosphorylation of YAP and TAZ on conserved serine 
residues that lead to sequestration and destabilization of YAP/TAZ in the 
cytoplasm (61,64,102). Mechanical cues and signals that affect cytoskeletal 
dynamics, such as those transduced by G-protein-coupled receptors (GPCRs), 
also control YAP/TAZ localization, both by regulating Hippo pathway activity and 
via Hippo pathway-independent cues (188). While the signals regulating YAP/TAZ 
localization are not completely understood, recent work indicates that precise 
control of these signals are required to maintain tissue homeostasis (189).  
Dysregulated YAP/TAZ activity has been implicated in head and neck 
cancers. For example, YAP expression has been shown to correlate with poor 
patient survival in head and neck cancers (91,92), and increased YAP levels and 
nuclear localization are associated with high-grade OSCC (92,93). TAZ 
overexpression has also been shown to be significantly associated with head and 
neck tumor size, histopathological grade, and reduced patient survival (92). 
Furthermore, elevated nuclear YAP/TAZ levels are known to promote resistance 
to several cancer treatments, including those commonly used for OSCC therapy, 
such as cisplatin and cetuximab (97,98,190). While evidence supports a role for 
YAP/TAZ in OSCCs, little is known about the downstream events regulated by 
YAP/TAZ, and at what step in cancerogenesis these factors may be involved.  
Given the potential importance of TAZ and/or YAP signaling, I sought to 
gain a better understanding of their roles in OSCC. To this end, I integrated the 
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use of patient tissue samples, functional assays in vitro and in vivo, genome-wide 
expression profiling, and analyses of publically available expression data from 
studies performed by “The Cancer Genome Atlas” (TCGA) groups. My 
observations have revealed that YAP localization is dysregulated in benign and 
early pre-malignant oral tissues, and that elevated YAP protein levels are evident 
in a subset of OSCCs. Further, I show that nuclear YAP and TAZ activity drive pro-
tumorigenic signals in OSCC cells in vitro, and that YAP and TAZ are necessary 
for OSCC development and metastasis in vivo. A global analysis of YAP/TAZ-
regulated gene expression exposed a transcriptional program associated with 
expression changes found in OSCC onset and progression. My data therefore 
highlight novel YAP/TAZ-regulated events in OSCC, and offer an important gene 
expression signature that may serve as a resource for OSCC detection and 
personalized therapeutic development strategies. 
Results 
Nuclear YAP accumulation marks pre-malignant dysplastic regions of the 
oral epithelium. 
The increased activity of the transcriptional regulator YAP has been 
implicated in the progression of oral squamous cell carcinoma (OSCC) 
(92,93,191,192). In particular, increased YAP levels have been associated with 
OSCC and other head and neck cancers, with subsets of these cancers exhibiting 
elevated nuclear YAP accumulation (93,191). Dysregulated nuclear YAP is known 
to drive overgrowth of several tissues (90), and thus YAP-driven cues may 
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contribute to early events in OSCC development. Since examination of benign and 
pre-malignant oral epithelial tissues has been limited, we set out to characterize a 
potential relationship between YAP and the pathology linked to OSCC 
predisposition. Specifically, we examined a range of tissues characterized as 
benign epithelial hyperplasia, mild and severe dysplasia, as well as 
morphologically normal adjacent epithelium from the oral cavity of human patients. 
Using immunofluorescence microscopy we observed very low levels of YAP in 
most cells found in the tissues of adjacent epithelium, except for YAP residing in 
the basal cell population, which exhibited relatively high levels in both the nuclear 
and cytoplasmic compartments (Figure 3.1). We observed the emergence of cells 
marked with prominent nuclear YAP beyond the basal cell population in spinous 
regions of dysplastic tissues, with highly enriched nuclear YAP in areas with severe 
dysplasia pathology (Figure 3.1). Interestingly, nuclear YAP was evident even in 
regions of benign epithelial hyperplasia (Figure 3.1). Our observations therefore 
suggest that predisposition to OSCC may be related to the dysregulation of YAP 
localization.  
Prior studies have suggested that amplification of the chromosomal region 
encoding YAP contributes to its aberrant expression in human head and neck 
squamous cell carcinoma cells (191,193). We therefore examined whether 
increased YAP expression may be linked to OSCC onset, and further 
characterized the prevalence of this potential dysregulation. For this, we made use 
of data from a large number of patient samples publically available from TCGA to
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Figure 3.1 - Nuclear YAP accumulates in pre-malignant oral tissues. Tissues 
from patients exhibiting hyperplasia, mild dysplasia, and severe dysplasia, as well 
as cytologically normal adjacent epithelium, were examined by H&E staining (top) 
and by immunofluorescence to detect YAP localization (the number of tissues 
examined is indicated). DAPI was used to stain nuclei. A zoomed in image from 
each sample is shown in the bottom panels, highlighting the YAP localization 
changes observed. Scale bars, 20 μm. Tissue staining and analysis was performed 
in collaboration with Trevor Packer, Munirah Almershed, and Maria Kukuruzinska. 
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examine potential YAP gene expression, amplification, and/or mutations. We also 
included TAZ in our analysis of the TCGA data. We found no evidence of 
amplification, deletion, or mutation of the genomic region encompassing YAP or 
TAZ in cancers originating from the oral cavity (using the Genomic Identification of 
Significant Targets in Cancer tool; data not shown). Further, we found that YAP 
(Figure 3.2A) and TAZ (Figure 3.2B) expression was not significantly altered with 
tumor grade or stage.  
Given that expression/mutation analysis may not reflect what is occurring 
with YAP protein levels, we obtained and examined protein from ten fresh OSCC 
tumors and their respective adjacent epithelia. Four of the tumors exhibited poorly 
differentiated pathology, and these tumors showed high levels of YAP compared 
to normal adjacent epithelia (Figure 3.3). Phosphorylation of YAP on Serine 127 
(pS127-YAP) induces the cytoplasmic sequestration of YAP (62,102), and 
correlates with YAP degradation (64). This post-translational modification was 
relatively low in the poorly differentiated tumors (Figure 3.3A and 3.3B), providing 
a potential explanation for the observed elevated YAP protein levels. The other six 
tumors I examined, which were characterized as moderately differentiated, 
showed no differences in YAP or pS127-YAP (Figure 3.3A and 3.3C). These data 
therefore suggest that dysregulated hypo-phosphorylated YAP might contribute to 
the distinct pathology of a subset of OSCCs.
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Figure 3.2 -YAP and TAZ expression in OSCCs. One-way ANOVA analysis 
showing (A) YAP or (B) TAZ expression with respect to TCGA OSCC tumor grade 
or stage data. A pairwise t test analysis comparing datasets revealed no significant 
expression changes. Analysis performed in collaboration with Liye Zhang, Vinay 
Kartha, and Stefano Monti. 
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Figure 3.3 - YAP expression and phosphorylation in OSCCs. Protein was 
extracted from poorly and moderately differentiated tumors, and associated 
adjacent epithelium (AE), and examined for YAP and phospho-S127-YAP levels 
by immunoblotting. Ponceau-S staining of the proteins on the immunoblotted 
membrane is shown as a loading control. Quantitation of the relative phospho-
S127-YAP to total YAP is also shown. A. A representative image of the observed 
changes in YAP expression and phosphorylation. B. Three poorly differentiated 
tumors and their associated AE after both a light and dark exposure. C. Three 
moderately differentiated tumors and their associated AE. 
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YAP/TAZ promote tumorigenic phenotypes in OSCC cells.  
To gain further insight into the contributions of YAP to OSCC development 
I utilized available OSCC cell lines to carry out functional assays following 
repressed or induced YAP activity. I started by examining YAP and pS127-YAP 
levels in lysates obtained from a panel of OSCC cell lines with different tumorigenic 
capacities: CAL27, SCC2, SCC9, SCC15, and SCC25 cells. I found that YAP 
levels were highest in the SCC2, which are cells that have aggressive metastatic 
properties in mouse xenograft models (194). YAP in the SCC2 cells was also hypo-
phosphorylated on S127 as compared to the other cells (Figure 3.4A). The relative 
differences in pS127-YAP were reflected in the compaction-induced sequestration 
of YAP into the cytoplasm of these cells, an event associated with contact-
mediated proliferation arrest (68) (Figure 3.4A). In particular, nuclear YAP levels 
in the SCC2 cells were not altered in response to cell compaction (Figure 3.4B). 
Thus, my observations suggest that increased hypo-phosphorylated nuclear YAP 
may relate to the aggressive behavior of SCC2 cells.  
Prior studies have indicated important roles for YAP and TAZ in the control 
of cell proliferation and survival (90). To test YAP activity in OSCC cells I decided 
to use the SCC2 and CAL27 cells as models for high and low nuclear YAP activity, 
respectively. First, SCC2 cells were transfected with siRNA to deplete YAP levels, 
and since TAZ might have complimentary roles, I also depleted TAZ, or both 
YAP/TAZ levels (Figure 3.5A). Analyses of cell numbers over time indicated that 
the knockdown of YAP, TAZ, or both YAP/TAZ decreased the ability of SCC2 cells 
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Figure 3.4 - Elevated levels of nuclear YAP are found in aggressive OSCC 
cells. A. A panel of oral cancer cell lines was examined by immunoblotting for 
endogenous YAP, phospho-S127-YAP, and GAPDH (loading control). 
Quantitation of relative phospho-S127-YAP to total YAP is shown. B. Oral cancer 
cell lines were examined by immunofluorescence for endogenous YAP localization 
at both low and high density. 
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Figure 3.5 - YAP/TAZ are necessary for SCC2 proliferation, survival, and 
migration. A. SCC2 cells were transfected with control siRNA (siCTL) or siRNA 
targeting TAZ (siTAZ), YAP (siYAP), or YAP and TAZ (siY/T), and lysates from 
these cells were examined by immunoblotting with the indicated antibodies 
including GAPDH (loading control). B. SCC2 knockdown cells were counted over 
6 days to measure their proliferative capacity. Cells from three experiments were 
counted and the average (± SE) for each day is shown. C. SCC2 knockdown cells 
were examined for caspase-3 and 7 activity using a Caspase-Glo 3/7 assay. The 
average (+SE) of three experiments is shown. D. Confluent monolayers of SCC2 
knockdown cells were wounded and examined for their ability to migrate after 12 
hours. Representative images are shown and the average wound healing (+SE) of 
three experiments is indicated. All statistics were calculated compared to the 
control sample using an unpaired Student t test and are represented as **, P < 
0.01; ***, P < 0.001. 
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to proliferate, with YAP knockdown affecting the cells more than TAZ knockdown, 
but YAP/TAZ knockdown having the most pronounced effect (Figure 3.5B). 
Examination of SCC2 cells that were depleted of YAP/TAZ also revealed that these 
cells had increased Caspase-3 and -7 (3/7) activity (Figure 3.5C), suggesting that 
these cells were undergoing increased apoptosis. Furthermore, knockdown of 
either YAP or TAZ decreased the ability of SCC2 cells to migrate in wound closure 
scratch assays, with knockdown of both YAP and TAZ almost completely halting 
cell migration (Figure 3.5D). 
I next examined whether induced nuclear YAP and TAZ activity could drive 
pro-tumorigenic behavior in non-metastatic CAL27 cells. For these studies, CAL27 
cells were engineered to express, in a doxycycline-inducible manner, the nuclear-
localized YAP-5SA mutant (S61A, S109A, S127A, S164A, S397A), or YAP-
5SA/S94A, which has an additional mutation that disrupts binding to the TEAD 
transcription factors (67,68) (Figure 3.6A). In contrast to YAP/TAZ depletion in 
SCC2 cells, ectopic expression of YAP-5SA increased the ability of CAL27 cells to 
proliferate (Figure 3.6B). YAP-induced proliferation relied on TEAD binding, as 
expression of the YAP-5SA/S94A mutant failed to increase proliferation (Figure 
3.6B). Expression of YAP-5SA, but not YAP-5SA/S94A, also reduced Caspase 3/7 
activity in the CAL27 cells (Figure 3.6C), suggesting that nuclear YAP-TEAD-
driven transcription induces pro-survival signals. Moreover, YAP-5SA, but not 
YAP-5SA/S94A, increased the ability of CAL27 cells to migrate (Figure 3.6D). 
Taken together, my observations indicate that nuclear YAP and TAZ promote the 
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Figure 3.6 - Nuclear YAP is sufficient to promote CAL27 proliferation, 
survival, and migration, dependent on YAP-TEAD binding. A. Doxycycline-
inducible CAL27 control cells, or cells expressing 3xFLAG-YAP(5SA) or 3xFLAG-
YAP(5SA/S94A) were lysed and examined by immunoblotting with the indicated 
antibodies including GAPDH (loading control). B. CAL27-expressing cells were 
counted over 14 days to measure their proliferative capacity. Cells from three 
experiments were counted and the average (±SE) for each day is shown. C. 
CAL27-expressing cells were examined for caspase-3 and 7 activity using a 
Caspase-Glo 3/7 assay. The average (+SE) of three experiments is shown. D. 
Confluent monolayers of CAL27-expressing cells were wounded and examined for 
their ability to migrate after 24 hours. Representative images are shown and the 
average wound healing (+SE) of three experiments is indicated. All statistics were 
calculated compared to the control sample using an unpaired Student t test and 
are represented as **, P < 0.01; ***, P < 0.001. 
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proliferation, survival, and migration of OSCC cell lines in vitro, and suggest that 
the increased nuclear YAP observed in OSCC is an important contributing factor 
to disease progression. 
To test whether YAP and TAZ drive pro-tumorigenic properties in OSCC 
cells in vivo, I knocked down YAP or YAP/TAZ in SCC2 cells and used them in 
tongue orthotopic xenograft tumor experiments in immune-compromised mice. I 
used SCC2 cells since they exhibit high nuclear YAP levels and have metastatic 
potential (194). To easily track tumor development and metastasis, we generated 
SCC2 cells expressing dsRED (SCC2-dsRED) and then engineered them to 
express control shRNA (shCTL), shRNA targeting YAP (shYAP), or shRNA 
targeting both YAP and TAZ (shYAP/TAZ). Stable knockdown was confirmed in 
these cells by immunoblotting (Figure 3.7A), and the cells were then injected into 
the tongue of mice (Figure 3.7B). Primary tumor growth was monitored with caliper 
measurements and also by IVIS imaging to locate dsRED-expressing cells. We 
found that YAP or YAP/TAZ knockdown decreased primary tumor volume, with 
YAP/TAZ suppressing tumor growth more dramatically (Figure 3.7B and 3.7C). 
Imaging after 22 days revealed abundant SCC2 cell metastasis, which was 
reduced with YAP knockdown, and almost completely ablated with YAP/TAZ 
knockdown (Figure 3.7C). Thus, our mouse experiments indicated that YAP and 
TAZ have important roles in OSCC tumor growth and metastasis, suggesting that 
dysregulated nuclear YAP in oral tissues is relevant for OSCC onset and 
progression.
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Figure 3.7 - YAP/TAZ are necessary for OSCC tumor growth and metastasis 
in vivo. A. SCC2-dsRED cells stably expressing control shRNA (shCTL) or shRNA 
targeting YAP (shYAP), or YAP and TAZ (shY/T) were lysed and examined by 
immunoblotting for the indicated proteins including GAPDH (loading control). B. 
SCC2-dsRED cells were injected into the tongue of nude mice and primary tumor 
volume was determined by caliper measurements at day 10, 15, 18, and 22, and 
are shown as the average (±SE; n=3 for vehicle control, n=9 for shRNA-expressing 
cells). C. SCC2-dsRED cells contributing to tumor formation and metastasis were 
visualized by IVIS fluorescent imaging at day 22 and representative images are 
shown. Total radiant efficiency of cells in the primary tumor and cells that 
metastasized throughout the animal body were quantitated and are shown as the 
average (+SE). Statistics comparing primary tumor size or metastasis of the 
knockdown cells to the control cells were performed using an unpaired Student t 
test and are represented as **, P < 0.01; ***, P < 0.001. Injections were performed 
in collaboration with Manish Bais. 
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YAP/TAZ promote a transcriptional program that is associated with human 
OSCC progression. 
The in vitro and in vivo studies suggested that the transcriptional activity of 
YAP and TAZ influence pro-tumorigenic events in OSCC cells. We therefore set 
out to understand YAP/TAZ-regulated transcription by using microarrays to 
compare the global expression profiles of SCC2 cells transfected with either 
control siRNA, or siRNA targeting TAZ, YAP, or both YAP/TAZ. Hierarchical 
clustering of the top 3000 genes with the highest MAD showed that the expression 
profiles from replicate samples clearly clustered next to each other. Notably, the 
expression profiles from the control cells and the TAZ-depleted cells clustered 
similarly, whereas those from cells depleted of YAP or YAP/TAZ had similar 
expression profiles (Figure 3.8). Thus, YAP appears to have more prominent 
transcriptional role in SCC2 cells compared to TAZ, which was supported by my 
functional experiments shown in Figure 3.5. Next, we carried out differential 
analyses of the control siRNA-treated samples versus the knockdown samples. 
For each treatment, we identified the signatures of up- (repressed) and down-
regulated (activated) genes with adjusted p-value ≤0.05 and fold-change ≥2. The 
number of genes included in each signature is summarized in Figure 3.8. 
To gain insight into whether the YAP- and TAZ-regulated gene expression 
signatures relate to OSCC onset and/or progression, we used the following two 
methods to make comparisons with gene expression data generated by TCGA: 1) 
we tested for gene enrichment in tumor grade or stage data using Gene Set
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Figure 3.8 - YAP/TAZ-regulated transcriptional events in OSCC. Microarrays 
were performed from samples isolated from SCC2 cells transiently transfected with 
control siRNA (siCTL) or siRNA targeting TAZ (siTAZ), YAP (siYAP), or YAP and 
TAZ (siY/T). Hierarchical clustering of the top 3000 genes with the highest MAD is 
shown. The number of up- and down-regulated genes (genes with adjusted P ≤ 
0.05 and fold change ≥ 2 compared with the control) that were identified from the 
microarray study is shown below. Analysis performed in collaboration with Liye 
Zhang, Vinay Kartha, and Stefano Monti. 
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Enrichment Analysis (GSEA); and 2) we used Adaptive Signature Selection and 
InteGratioN (ASSIGN) to capture the coordinated co-expression of YAP/TAZ 
targets reflecting the corresponding regulators’ activity. Our GSEA analysis 
revealed a significant enrichment (nominal p-values ≤0.05) for genes activated by 
YAP or YAP/TAZ (i.e. decreasing in the microarrays with knockdown) when 
compared to genes with elevated expression in tumor versus adjacent epithelium 
(Figure 3.9A). Enrichment of the YAP- and YAP/TAZ-regulated gene expression 
signature was preserved with elevated tumor grade (Figure 3.9A) and tumor stage 
(Figure 3.9B), even when comparing aggressive stage IV OSCCs to earlier stages 
(Figure 3.9B), suggesting that in addition to events necessary for tumor onset, 
YAP/TAZ activities also control processes required for late stage OSCC 
progression. Similar data were obtained from ASSIGN analyses, which showed a 
significant upward trend of the YAP/TAZ activity score as a function of an 
increasing tumor grade and stage (Figure 3.9C and 3.9D). Together these data 
indicate that a subset of genes dysregulated in human OSCCs is associated with 
aberrant YAP/TAZ-activity.  
The YAP/TAZ-regulated gene expression signature included canonical 
YAP/TAZ targets, such as CTGF or CYR61. However, no significant change in the 
expression of these genes was observed with respect to tumor onset, tumor grade, 
or tumor stage (Figure 3.10A), suggesting that the roles of YAP/TAZ in OSCCs 
extend beyond what has been characterized in other contexts. To better 
understand the cues regulated by YAP/TAZ in OSCC we clustered the identified 
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Figure 3.9 - YAP/TAZ-regulated transcriptional events correlate with OSCC tumor grade and stage. We tested 
for the enrichment of the YAP- and YAP/TAZ-regulated expression changes in TCGA data (n=193 samples) by 
GSEA. Enrichment nominal p-values are summarized for the analysis of (A) tumor grade versus adjacent epithelium 
(AE), with a GSEA curve for the YAP/TAZ activated genes enriched (p-value highlighted in grey) shown below and 
(B) for the analysis of high tumor stage versus low tumor stage, with a GSEA curve for the YAP/TAZ activated genes 
in > Stage II vs Stage I-II (p-value highlighted in grey) shown below. We also used the ASSIGN algorithm to infer the 
level of YAP/TAZ activity in TCGA OSCC from the coordinated expression of the set of YAP/TAZ-regulated genes 
identified in the microarray. ANOVA was performed to test for the association between the YAP/TAZ activity scores 
and tumor grade or stage, which revealed significant association of the YAP/TAZ-activity with both (p-values < 2e-
16). Samples were then ranked by increasing activity score and their corresponding (C) tumor grade and (D) tumor 
stage information is shown. Samples with missing tumor grade or stage information were excluded from the analysis 
(195). Analysis performed in collaboration with Liye Zhang, Vinay Kartha, and Stefano Monti. 
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Figure 3.10 - Expression of YAP/TAZ-regulated genes in OSCC tumors. Box 
plots showing the expression of (A) canonical YAP/TAZ targets, (B) YAP/TAZ-
regulated cell cycle genes, (C) YAP/TAZ-regulated survival gene BIRC5, and (D) 
YAP/TAZ-regulated transcription factors TEAD1 and TEAD4 with respect to OSCC 
tumor grade (G0: n=23; G1: n=20; G2: n=106; G3/4: n=40) and stage (S0: n=23; 
I: n=11; II: n=33; III: n=24; IVA/IVB: n=86). TEAD4 expression is significantly 
induced with OSCC tumor grade (one-way ANOVA; P = 3.51 e-05) and stage (one-
way ANOVA; P = 0.0012). Pairwise t tests of expression between groups is also 
shown, and represented as *, P < 0.05; **, P < 0.01; and ***, P < 0.001. Analysis 
performed in collaboration with Liye Zhang, Vinay Kartha, and Stefano Monti. 
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gene expression signature with TCGA-derived OSCC tumor grade and stage 
expression changes. Clustering uncovered clear segregation of adjacent 
epithelium (white marked columns in Figure 3.11A) and tumor samples (green 
marked columns in Figure 3.11A), and further revealed tumor-associated sub-
clusters of YAP/TAZ-regulated genes, the most prominent of which correlated with 
genes induced in expression by YAP/TAZ (yellow cluster in Figure 3.11A). A more 
focused cluster analysis of only these activated genes revealed two major sub-
groups, which we termed Cluster A and Cluster B (Figure 3.11B). Annotation of 
these gene clusters by pathway hyper-enrichment analysis yielded a strong 
enrichment of cell cycle-related pathways in Cluster A, all of which showed 
increased expression with tumor grade or stage when examined in the TCGA 
datasets (Figure 3.10B and 3.10C). Cluster B showed enrichment for genes 
responding to signals mediated by AP1, Hippo, TGFβ, and WNT pathways. 
Notably, several transcription factors relevant to tumor progression were also 
altered in Cluster B, and included TEAD1, TEAD4, ETS1, JUN, PBX3, RUNX2 and 
SOX9.  
To validate whether the genes identified in Clusters A and B were indeed 
regulated by YAP and TAZ, I examined the expression of subset of these genes 
by RT-qPCR in SCC2 cells transfected with control siRNA, or siRNA targeting TAZ, 
YAP, or both YAP/TAZ, as well as in CAL27 cells that expressed (24 h of ectopic 
expression) the nuclear YAP-5SA mutant or the transcriptionally defective YAP-
5SA-S94A mutant. I initially focused on genes critical for cell cycle progression 
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Figure 3.11 - Pathway enrichment in YAP/TAZ-regulated gene signatures. OSCC tumor grade and tumor stage 
data obtained from TCGA was projected onto (A) the entire YAP/TAZ-regulated expression signature identified from 
the microarray studies, or (B) only the YAP/TAZ-activated expression signature, and a heatmap of the clustered data 
is shown. Two notable YAP/TAZ-activated gene clusters were identified, and selected data from a pathway 
enrichment analysis of these genes are shown to the right (196-199). Analysis performed in collaboration with Liye 
Zhang, Vinay Kartha, and Stefano Monti. 
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(CCNE2, CDK2, CDC6, PCNA, AURKA, PLK4), and pro-survival (BIRC5), both of 
which were associated with Cluster A in Figure 3.11B. I found that knockdown of 
YAP/TAZ in SCC2 cells strikingly reduced the expression of all cell cycle and 
survival genes found in Cluster A (Figure 3.12). YAP knockdown also repressed 
the expression of these genes, some of which mirrored YAP/TAZ knockdown, 
while others were less affected, suggesting that TAZ redundantly regulates the 
expression of some of these genes. TAZ knockdown alone, however, had minor 
effects on the expression of almost all of these genes, suggesting that YAP/TAZ 
redundancy may only be revealed upon YAP deficiency in these cells. These same 
cell cycle and pro-survival genes were significantly induced by YAP-5SA 
expression in CAL27 cells (Figure 3.13), but were not affected by the expression 
of the transcriptionally defective YAP-5SA/S94A mutant, suggesting that nuclear 
YAP-TEAD activity directly regulates the expression of these genes. The 
transcription factors identified in Cluster B were all down-regulated following 
YAP/TAZ and YAP knockdown in SCC2 cells (Figure 3.12). However, the 
expression of these genes was largely unaffected following YAP-5SA expression 
in CAL27 cells, suggesting that some of these genes may not be direct YAP 
targets, or that they require additional factors or signals present in more 
progressed OSCCs for YAP-directed regulation. Interestingly, the exception was 
the regulation of TEAD1 and TEAD4, as the expression of both of these TEAD 
family members was increased by YAP-5SA, but not by the YAP-5SA/S94A 
mutant, in CAL27 cells (Figure 3.13). Further, analysis of gene expression across 
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Figure 3.12 - YAP/TAZ are necessary for target gene expression in SCC2 cells. SCC2 cells were transiently 
transfected with control siRNA (siCTL) or siRNA targeting TAZ (siTAZ), YAP (siYAP), or YAP and TAZ (siY/T). 
Relative expression of genes indicated in the microarray analysis was determined by RT-qPCR. All data are relative 
to siCTL (dashed line) and are shown as the average of three experiments (+SE). Genes are grouped together by 
function including knockdown efficiency (blue), cell-cycle regulation (red), pro-survival (green), and transcription 
factors (purple). Statistics comparing to the control cells (dashed line) were calculated using an unpaired Student t 
test and are represented as *, P < 0.05; **, P < 0.01; and ***, P < 0.001. 
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Figure 3.13 - Nuclear YAP is sufficient to promote expression of some target 
genes in CAL27 cells dependent on YAP-TEAD binding. Doxycycline-inducible 
CAL27 control cells or cells expressing 3xFLAG-YAP(5SA) or 3xFLAG-
YAP(5SA/S94A) were treated with doxycycline. Relative expression of genes 
indicated in the microarray analysis was determined by RT-qPCR. All data are 
relative to siCTL (dashed line) and are shown as the average of three experiments 
(+SE). Genes are grouped together by function including cell-cycle regulation 
(red), pro-survival (green), and transcription factors (purple). Statistics comparing 
to the control cells (dashed line) were calculated using an unpaired Student t test 
and are represented as *, P < 0.05; **, P < 0.01; and ***, P < 0.001. 
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tumor grade using TCGA data OSCC onset, as increased nuclear YAP 
accumulation can be detected showed that TEAD4 is induced in expression with 
tumor onset, and further increases with higher tumor grade and stage (Figure 
3.10D). TEAD1 did not show the same trends (Figure 3.10D). Thus, these data 
suggest that TEAD4 may function as a relevant YAP/TAZ target that initiates a pro-
tumorigenic feed-forward cascade that contributes to the onset and progression 
OSCC.  
Discussion 
This study provides evidence that the transcriptional regulators YAP and 
TAZ have important roles in the onset and progression of human OSCC. Notably, 
I have found that YAP localization is dysregulated in regions predisposed to OSCC 
onset, as increased nuclear YAP accumulation can be detected in epithelial cells 
of hyperplastic and dysplastic tissues. Thus, altered YAP localization correlates 
with the early transformation of oral epithelial cells, suggesting that nuclear YAP 
promotes their progression to a malignant state. Indeed, knockdown of YAP in 
SCC2 cells inhibited the ability of these cells to proliferate in vitro, and reduced the 
ability of these cells to generate tongue tumors in vivo. YAP knockdown in CAL27 
cells also inhibited cell proliferation and anchorage-independent growth (192). 
Moreover, ectopic expression of a nuclear-localized YAP mutant in CAL27 cells 
promoted cell proliferation, indicating that nuclear YAP is sufficient to drive cell 
proliferation. Ectopic expression of nuclear-localized YAP also increased the ability 
for CAL27 cells to promote wound closure in vitro, and while I cannot rule out that 
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these differences do not relate to proliferative alterations, my observations suggest 
that nuclear YAP activity is also sufficient to drive cell migration. Due to technical 
issues we were unable to similarly examine the localization of TAZ in human 
tissues, but given that common regulatory signals control YAP and TAZ 
localization (69), and that TAZ plays an important role in other cancer cells 
(12,177), it is likely that dysregulated TAZ localization also contributes to early 
OSCC development. Supporting this premise, I found that knockdown of both YAP 
and TAZ in SCC2 OSCC cells severely reduced their proliferation, induced pro-
apoptotic cues, and halted their wound closure potential in vitro, beyond the 
knockdown of either YAP or TAZ alone. Additionally, knockdown of both YAP and 
TAZ dramatically reduced primary tumor growth in vivo, more so than YAP 
knockdown alone. Thus, YAP and TAZ have redundant pro-tumorigenic roles, 
which may be the case for other malignancies in addition to OSCC. 
While our observations indicate accumulation of nuclear YAP in tissues 
predisposed to form OSCC, how this dysregulation arises is less clear. 
Interrogation of TCGA datasets showed no indication of general increases in YAP 
(or TAZ) expression or genomic alterations with OSCC onset, or altered 
expression of core Hippo pathway components known to regulated YAP/TAZ 
localization. Given the close association between epithelial cell polarity cues and 
the control of YAP localization (70,71), and the observed epithelial polarity 
changes that occur with OSCC onset (200), one possibility is that altered epithelial 
polarity cues may contribute to the dysregulation of YAP. Another unresolved 
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question relates to why only subsets of tumors exhibit abundant levels of YAP 
protein. My analysis showed that four out of the ten tumors (ranging from 
moderately to poorly differentiated) that I examined had elevated YAP levels. While 
the increased YAP levels in these distinct tumors may result from amplified 
expression of YAP, as suggested by prior studies (191,193), they may also relate 
to alternative mechanisms of post-transcriptional control of YAP stability and 
localization. Phosphorylation of YAP on S127 was reduced in tumors with elevated 
YAP, suggesting that defective Hippo pathway signaling likely contributes to these 
aberrant YAP levels. Notably, the tumors I identified with high YAP levels were 
characterized as poorly differentiated, suggesting that YAP may contribute to 
tumor progression. High YAP levels with prominent nuclear localization were 
observed in the basal layer of adjacent histopathologically normal epithelia, which 
is similar to that observed in the basal progenitors of the epidermis (71), proximal 
lung epithelium (201,202), and a range of other epithelial stem cell populations 
throughout development (69). Thus, nuclear YAP activity may facilitate the oral 
epithelial progenitor state and possibly contribute to stem cell-like properties 
observed in aggressive OSCCs. 
The pro-tumorigenic activity of YAP and TAZ rely on their transcriptional 
properties (67,88). Using global gene expression analysis following the knockdown 
of YAP/TAZ in OSCC cells we have identified a transcriptional program that is 
regulated by these factors. This YAP/TAZ expression signature correlates with 
gene expression changes identified by TCGA in OSCC, indicating that YAP/TAZ 
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is broadly dysregulated with OSCC onset. Strikingly, genes induced in expression 
by YAP/TAZ (i.e. genes repressed following YAP/TAZ knockdown) are significantly 
associated with OSCC progression, as the expression changes are maintained 
with advancing tumor grade and tumor stage. This includes stage IV tumors, which 
have the lowest 5-year survival rates (203). Our data showing that YAP/TAZ may 
promote OSCC cell migration and progression to a metastatic state in mouse 
orthotopic tongue tumor models suggest that YAP/TAZ participate in pro-
metastatic events in OSCC, as is the case in other malignancies (12,88), but 
further work is required to clarify this possibility.   
Hierarchical clustering analysis of the YAP/TAZ-induced genes with OSCC 
tumor grade and stage progression revealed two clusters that suggest YAP/TAZ 
function in OSCC. One of these clusters (Cluster A in Figure 3.11B) was enriched 
for genes critical for cell cycle progression, and likely explains the pro-proliferation 
roles that YAP/TAZ play in OSCC cells. Genes regulated by the ATR- and E2F- 
transcription factors are enriched in this cluster, suggesting that YAP/TAZ may 
direct the activity of these transcription factors to overcome cell cycle checkpoints. 
The second cluster (Cluster B in Figure 3.11B) was enriched for genes that 
respond to cancer-related signaling pathways, such as those regulated by TGFβ 
and WNT growth factors. Nuclear YAP and/or TAZ synergize with TGFβ-activated 
SMAD transcription factors to promote pro-tumorigenic events (1,126), and thus, 
it is likely that nuclear YAP/TAZ promote these signals in OSCC. Similarly, nuclear 
YAP/TAZ facilitate WNT-induced signals (120,122), which have key roles in the 
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development of OSCC (178). WNT and TGFβ signaling both promote EMT, which 
is a process implicated in the induction of tumor-initiating properties (11). EMT-
related genes were enriched in the YAP/TAZ-regulated transcriptional signature, 
as were gene targets of the stem cell-regulating transcription factor OCT4. Thus, 
the YAP/TAZ-induced transcriptional program may influence tumor-initiating 
properties that are associated with aggressive OSCC. Additional transcription 
factors implicated in cancer progression were also regulated by YAP/TAZ, 
including SOX9, which has recently been described as a target of YAP in 
esophageal cancers (204). Notably, members of the TEAD family were induced by 
YAP/TAZ, and increased expression of TEAD4 was significantly elevated with 
increased OSCC grade and stage. Thus, early increases in nuclear YAP/TAZ 
localization may initiate a feed-forward mechanism that promotes the assembly of 
YAP/TAZ-TEAD complexes. Given that binding to TEAD transcription factors 
drives YAP/TAZ nuclear accumulation (66), such a feed-forward mechanism may 
contribute to the elevated nuclear YAP/TAZ observed with OSCC development.  
Taken together these observations indicate that YAP/TAZ are important 
factors contributing to OSCC biology. Our data highlight the importance of 
examining changes beyond single gene expression, mutation, and/or genomic 
alterations that correlate with cancer tissues, as our focused analysis of the 
YAP/TAZ-regulated signature identifies and connects tumor-associated 
expression changes that may be otherwise overlooked. Given that YAP/TAZ are 
dysregulated early in the onset of OSCC, further understanding the YAP/TAZ-
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regulated transcriptional events and linking them to other cancer-related signaling 
networks may offer new insight into OSCC. Moreover, given the emergence of 
small molecules that target YAP/TAZ activity, novel therapeutic approaches may 
evolve that can hopefully reduce this devastating disease. 
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CHAPTER IV - YAP/TAZ DIRECT TRANSFORMING GROWTH FACTOR Β-
INDUCED TUMORIGENIC PHENOTYPES IN BREAST CANCER CELLS 
Disclaimer: This chapter is adapted from Hiemer, S. E., Szymaniak, A. D., and 
Varelas, X. (2014) The transcriptional regulators TAZ and YAP direct transforming 
growth factor β-induced tumorigenic phenotypes in breast cancer cells. Journal of 
Biological Chemistry 289, 13461-13474 (177) 
Abstract 
Uncontrolled Transforming growth factor β (TGFβ) signaling promotes 
aggressive metastatic properties in late-stage breast cancers. However, how 
TGFβ-mediated cues are directed to induce late-stage tumorigenic events is poorly 
understood, particularly given that TGFβ has clear tumor suppressing activity in 
other contexts. Here I demonstrate that the transcriptional regulators YAP and TAZ 
(YAP/TAZ), key effectors of the Hippo pathway, are necessary to promote and 
maintain TGFβ-induced tumorigenic phenotypes in breast cancer cells. 
Interactions between YAP/TAZ, TGFβ-activated SMAD2/3, and TEAD 
transcription factors reveal convergent roles for these factors in the nucleus. 
Genome-wide expression analyses indicate that YAP/TAZ, TEADs and TGFβ-
induced signals coordinate a specific pro-tumorigenic transcriptional program. 
Importantly, genes cooperatively regulated by YAP/TAZ, TEAD, and TGFβ, such 
as the novel targets NEGR1 and UCA1, are necessary for maintaining tumorigenic 
activity in metastatic breast cancer cells. Nuclear YAP/TAZ also cooperate with 
TGFβ signaling to promote phenotypic and transcriptional changes in non-
  82 
tumorigenic cells to overcome TGFβ repressive effects. My work thus identifies 
crosstalk between nuclear YAP/TAZ and TGFβ signaling in breast cancer cells, 
revealing novel insight into late-stage disease-driving mechanisms. 
Introduction 
Elevated nuclear levels of the transcriptional regulators YAP and TAZ are 
associated with a broad range of aggressive cancers (90). For instance, the extent 
of nuclear YAP or TAZ levels corresponds with breast cancer tumor grade 
(12,94,95). In breast cancer cells, enhanced nuclear YAP and TAZ levels promote 
oncogenic transformation and endow cells with tumorigenic properties, including 
the ability to proliferate, subvert apoptotic cues, migrate, invade, and grow under 
anchorage-independent conditions (10,68,101,102,105). Moreover, high nuclear 
TAZ levels induce CSC-like activity (12,88), and promote evasion of certain breast 
cancer drug therapies (12,96). Thus, understanding the roles of YAP/TAZ is critical 
for directing efficient breast cancer therapies. 
The tumor-initiating activity of YAP/TAZ relies on their binding to the TEAD 
family of transcription factors (TEAD1-4) (67,87,88), indicating that together these 
factors direct a tumorigenic transcriptional program. Supporting this premise, 
YAP/TAZ-TEAD complexes directly promote the expression of oncogenic factors, 
such as CTGF and CYR61 (67,87), which contribute to human breast cancer 
progression (205). Nuclear YAP/TAZ activity is highly regulated, and governed in 
large part by the Hippo pathway-regulated LATS1 and LATS2 kinases (59). 
LATS1/2 kinases phosphorylate YAP/TAZ on conserved Serine residues, which 
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promotes 14-3-3 binding and subsequent sequestration in the cytoplasm (61,62), 
and also prime YAP/TAZ for further phosphorylation by CK1ε/δ-kinases that evoke 
YAP/TAZ degradation via proteasome-dependent mechanisms (63,64). Additional 
phosphorylation events destabilize TAZ, including those regulated by WNT, PI3K, 
and GSK3β (65,121). Thus, dysregulation of multiple upstream signals likely 
contributes to the hypo-phosphorylation and stabilization of nuclear YAP/TAZ 
activity in cancer.  
YAP/TAZ modify the activity of other transcription factors besides TEADs, 
including the Transforming growth factor-beta (TGFβ)-activated SMAD complexes 
(174). TGFβ is the prototypic member of a family of secreted factors that regulates 
numerous developmental and homeostatic processes (130). SMAD2 and SMAD3 
(SMAD2/3) are the primary mediators of TGFβ-induced transcription. SMAD2/3 
are phosphorylated by TGFβ-bound membrane receptors, which induces binding 
to SMAD4 (138,140), forming active transcriptional complexes that accumulate in 
the nucleus upon binding to YAP/TAZ (126). In cancer the role of TGFβ is complex, 
as it can suppress early oncogenic events but also promote aggressive late-stage 
metastatic phenotypes (146,147). Several lines of evidence indicate that TGFβ, 
like YAP/TAZ, promotes aggressive tumorigenic properties in late-stage breast 
carcinomas (11,167). What mechanistically distinguishes between TGFβ-
dependent responses is poorly understood. 
Given that YAP/TAZ bind to SMAD transcription factors and direct TGFβ 
signaling in other contexts (70,126,128), I sought to characterize whether 
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YAP/TAZ define TGFβ-mediated tumorigenic cues in breast cancer cells. My 
observations indicate that TGFβ-induced tumorigenic events, such as increased 
cell migration, invasion, and anchorage-independent growth, require YAP/TAZ. My 
data also indicate that like YAP/TAZ, the TEAD transcription factors interact with 
TGFβ-induced SMAD2/3 in the nucleus, suggesting that YAP/TAZ-TEAD-
SMAD2/3 complexes coordinate transcriptional events in a concerted manner. 
Genome-wide microarray analysis of gene expression changes that occur upon 
knockdown of YAP/TAZ or TEADs, or inhibition of TGFβ signaling, revealed that 
YAP/TAZ, TEAD, and TGFβ regulate overlapping target genes. Interestingly, the 
direct gene targets NEGR1 and UCA1, which are synergistically regulated by 
YAP/TAZ, TEAD, and TGFβ, are necessary for maintaining tumorigenic activity in 
metastatic breast cancer cells, suggesting that the convergence of YAP/TAZ-
TEAD-TGFβ signals is critical for driving late-stage breast cancer phenotypes. 
Supporting this premise, expression of nuclear-localized YAP or TAZ mutants 
direct transcriptional events that sensitize untransformed breast cancer cells to 
adopt tumorigenic phenotypes in response to TGFβ, while also suppressing TGFβ-
induced cytostasis. These findings reveal novel crosstalk between TGFβ and 
Hippo signaling that I propose is important for late stage tumorigenic events in 
breast cancer. 
  85 
Results 
Nuclear YAP/TAZ are required to promote TGFβ-induced tumorigenic 
phenotypes in breast cancer cells 
In cancer the role of TGFβ is complex, as it can suppress early oncogenic 
events, such as cell cycle progression, but also promote late-stage metastatic 
phenotypes (146,147). What mechanistically distinguishes between TGFβ-
dependent responses is poorly understood. Several lines of evidence indicate that 
nuclear YAP/TAZ, like TGFβ, induce tumorigenic properties in late-stage breast 
carcinomas (11,167). In untransformed mammary epithelium, YAP/TAZ 
localization is restricted to the cytoplasm by cell compaction/polarity-regulated 
cues (68,70). Dysregulation of cell polarity cues, which is a hallmark of cancer 
progression (6), induces nuclear YAP/TAZ localization. Given our prior work 
showing that YAP/TAZ bind to and regulate the localization and activity of TGFβ-
activated SMAD transcription factors (70,126), I sought out to test whether TAZ 
and/or YAP promote TGFβ-induced tumorigenic events. I began my analysis by 
examining the relationship between YAP/TAZ localization and the TGFβ-induced 
cytostatic response in a panel of mammary epithelial and breast cancer cell lines. 
Based on published data, I divided the panel into cells that are responsive to TGFβ-
induced cytostasis (MCF10A, BT20, HMLE, HS578T, MCF7, and MCF12) and 
cells in which TGFβ induces pro-tumorigenic signals, but not growth arrest (MDA-
MB-231, MDA-MB-231-LM2-4, SKRB3, and SUM149) (206-213). Interestingly, I 
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observed that cells displaying high levels of nuclear YAP/TAZ correlate with those 
in which TGFβ induces tumorigenic cues (Figure 4.1). 
Tumor-initiating cell properties are associated with the ratio of glycoprotein 
cell surface markers CD24 and CD44. High levels of CD44 to low levels of CD24 
(CD44high/CD24low) positively correlate with the cell’s ability to self-renew and 
differentiate (11). I have found that CD44high/CD24low populations also correlate 
with nuclear YAP/TAZ (Figure 4.2). In MDA-MB-231-LM2-4 cells (herein referred 
to as LM2-4) metastatic breast cancer cell line (214), a highly aggressive derivative 
of triple-negative basal subtype MDA-MB-231 cells (215), the cells have higher 
CD44 levels compared to the parental MDA-MB-231 cells and non-tumorigenic 
human MCF10A mammary epithelial cells (Figure 4.2). This correlates with both 
increased nuclear YAP/TAZ localization at high density (Figure 4.1), increased 
TAZ levels, and decreased phospho-S127-YAP levels (Figure 4.3). 
To further investigate the relationship between YAP/TAZ and TGFβ, I 
sought to determine the roles of nuclear YAP/TAZ in the LM2-4 cell line. A fraction 
of LM2-4 cells in culture are capable of generating clonal mammospheres under 
anchorage-independent conditions (Figure 4.4), which is often used as a measure 
of the self-renewing potential of tumorigenic cells in vitro (216). TGFβ treatment of 
LM2-4 cells led to dramatic increases in the number and size of mammospheres 
observed (Figure 4.4A and 4.4B), similar to that observed with TGFβ treatment of 
other mammary cells (11). When the self-renewing properties of the cells within 
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Figure 4.1 - TAZ and YAP localization in a panel of breast cancer cell lines. A panel of breast cancer cell lines 
was divided by TGFβ-induced cytostasis and TGFβ-induced tumorigenic responses and examined by 
immunofluorescence for endogenous TAZ and YAP localization. 
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Figure 4.2 - Aggressive breast cancer cells have high CD44 and low CD24 
expression. MCF10A, MDA-MB-231, and LM2-4 cells were stained for CD44-
FITC and CD24-PE and analyzed by flow cytometry to determine protein 
expression. Data from 10,000 events from each cell line are shown. 
  89 
 
 
Figure 4.3 - Protein expression in MCF10A, MDA-MB-231, and LM2-4 cells. 
MCF10A, MDA-MB-231, and LM2-4 cells were left untreated or treated with TGFβ 
or SB-431542 (SB) for 2 hours. Cells were lysed and analyzed by immunoblotting 
with the indicated antibodies including GAPDH (loading control). 
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Figure 4.4 - YAP/TAZ are required for TGFβ-induced tumorisphere formation 
and propagation. LM2-4 cells were transiently transfect with control siRNA 
(siCTL) or siRNA targeting TAZ (siTAZ), YAP (siYAP), or YAP and TAZ (siY/T). 
Cells were left untreated, treated with TGFβ or SB-431542 (SB) +TGFβ, and grown 
in anchorage-independent conditions. A. Representative images of primary 
mammosphere colonies. B. Primary mammospheres were quantitated, measuring 
the number of colonies formed (left) and the size of each colony (right). Knockdown 
efficiency is indicated below. C. Primary mammospheres were passaged into 
secondary spheres. Secondary mammospheres following SB-431542 treatment, 
or transfection with siTAZ, siYAP, or siY/T were unable to be determined due to 
low numbers. Three independent experiments from each condition were 
quantitated. Black error bars represent the average (+SE) and red error bars 
represent the average (±SE). Statistics were performed using an unpaired Student 
t test and are represented as *, P < 0.025; **, P < 0.005; ***, P < 0.0001. 
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the mammospheres were assessed for their ability to form secondary clonal 
spheres (216), I found that TGFβ also promoted secondary mammosphere 
formation (Figure 4.4C). Co-treatment of the cells with the TGFβ-receptor agonist 
SB-431542 abolished the formation of primary mammospheres, validating that the 
observed effects are indeed generated via canonical TGFβ-receptor-mediated 
signals (217,218) (Figure 4.4A and 4.4B). As expected, SB-431542 treatment 
eliminated the TGFβ-induced phosphorylation of SMAD2 and SMAD3 in these 
cells (Figure 4.3). Individual TAZ or YAP knockdown also repressed the number 
and size of TGFβ-induced mammospheres (Figure 4.4A and 4.4B). However, 
simultaneous knockdown of both TAZ and YAP dramatically reduced primary 
mammosphere formation and prevented secondary mammosphere formation 
(Figure 4.4), indicating redundant roles for TAZ and YAP in transducing TGFβ-
mediated cues required for anchorage-independent growth and tumor initiating 
properties. 
I further investigated other hallmark tumorigenic properties that may be 
mediated by TGFβ and YAP/TAZ in metastatic breast cancers, including cell 
migration and invasion (6). I found that treatment of LM2-4 cells with TGFβ led to 
increases in cell migration in an in vitro wound-healing scratch assay (Figure 
4.5A), similar to prior work (219). As expected, co-treatment with TGFβ-receptor 
agonist SB-431542 blocked TGFβ-induced cell migration (Figure 4.5A). 
Simultaneous knockdown of YAP/TAZ using siRNA also abolished TGFβ-induced 
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Figure 4.5 - YAP/TAZ are required for TGFβ-induced migration and invasion. 
A. LM2-4 cells were transiently transfected with control siRNA (siCTL) or siRNA 
targeting TAZ (siTAZ), YAP (siYAP), or YAP and TAZ (siY/T). Cells were left 
untreated, treated with TGFβ or SB-431542 (SB) +TGFβ. Monolayers were 
wounded and analyzed for cell migration. B. LM2-4 cells stably expressing control 
shRNA (shCTL), or shRNA targeting YAP and TAZ (shY/T) were treated with TGFβ 
or SB-431542 +TGFβ and incubated in three-dimensional Matrigel culture 
conditions. Representative images from three independent experiments are 
shown. 
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LM2-4 cell migration (Figure 4.5A). Similarly, SB-431542 treatment or shRNA-
mediated YAP/TAZ knockdown abolished the ability of three-dimensional colonies 
of LM2-4 cells to invade into surrounding Matrigel matrix in the presence of TGFβ 
(Figure 4.5B). Taken together, my observations indicate that YAP/TAZ are critical 
mediators of TGFβ-induced tumorigenic events, including mammosphere 
formation, cell migration, and invasion. 
YAP/TAZ, TEADs, and SMADs converge to regulate a TGFβ-induced 
transcriptional program in breast cancer cells 
Studies indicate that YAP/TAZ-induced cell transformation relies on the 
recruitment of YAP/TAZ to DNA by the TEAD family of transcription factors 
(TEAD1-4) (67,87). TAZ and YAP also bind TGFβ-activated SMAD complexes to 
control SMAD localization and activity in a variety of cell types, including mammary 
epithelial cells (70,126). Recent work has shown that YAP/TAZ-TEAD-SMAD2/3 
complexes control transcriptional events important for maintaining human 
embryonic stem cell pluripotency (127). Thus, I hypothesized that similar 
complexes are also present in late stage breast cancers such that TEAD and 
SMAD transcription factors cooperatively facilitate YAP/TAZ-mediated tumorigenic 
activity. I found that TEAD2 and TEAD4 associate with SMAD3, as well as YAP 
(Figure 4.6), and these interactions were unaffected by stimulation with a 
constitutively active TGFβ receptor (TGFβR1-T240D (220)). Given that YAP/TAZ 
exhibit a predominantly nuclear localization in LM2-4 cells, and SMAD2/3 nuclear 
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Figure 4.6 - TEAD2 and TEAD4 interact with SMAD3 and YAP. HEK293T cells 
expressing HA-SMAD3, MYC-YAP, His-TGFβR1-T240D, and FLAG-TEAD2 (A) or 
FLAG-TEAD4 (B) were lysed and subjected to IP with a FLAG antibody followed 
by immunoblotting with the indicated antibodies. 
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localization is induced upon TGFβ treatment (Figure 4.7), I speculated that 
YAP/TAZ-TEAD might be interacting with TGFβ-activated SMAD2/3 to specify pro-
tumorigenic transcriptional events. To acquire both protein interaction and 
localization information, I performed in situ PLA. PLA is a sensitive technique used 
to visualize the localization and association of endogenous protein complexes 
(proteins localized within 40nm of each other) by microscopy (221). Using PLA, I 
observed YAP/TAZ-SMAD2/3 interactions in both the nucleus and cytoplasm of 
untreated LM2-4 cells (Figure 4.8A). Upon TGFβ treatment, nuclear YAP/TAZ-
SMAD2/3 binding became much more apparent in the nucleus (Figure 4.8A), 
consistent with nuclear YAP/TAZ-SMAD2/3 complexes directing transcriptional 
events (70,126). I also detected endogenous TAZ-TEAD1 interactions in the 
nucleus of LM2-4 cells with or without TGFβ stimulation (Figure 4.8B), which were 
increased slightly upon TGFβ treatment (Figure 4.8B). TEAD1-SMAD2/3 
interactions were readily detected in the nucleus of LM2-4 cells, particularly after 
TGFβ treatment (Figure 4.8C), suggesting these complexes stabilize upon nuclear 
accumulation of SMADs. Taken together, my observations indicate that YAP/TAZ, 
TEAD, and SMAD interact in TGFβ-stimulated metastatic breast cancer cells, and 
suggest that they may form transcriptional complexes that function together in the 
nucleus. 
To explore the possible overlap in transcriptional activity by YAP/TAZ, 
TEAD, and SMAD complexes in tumorigenesis, I used microarrays to compare the 
global expression profiles of LM2-4 cells treated as follows: 1) transfected with 
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Figure 4.7 - SB-421542 or TGFβ treatment do not affect TAZ or YAP 
localization. LM2-4 cells were left untreated or treated with SB-431542 (SB) or 
TGFβ for 2 hours and were examined by immunofluorescence for endogenous 
TAZ or YAP localization (left) or YAP and SMAD2/3 localization (right). Nuclei were 
visualized with Hoechst stain. Representative images are shown. 
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Figure 4.8 - YAP/TAZ, TEADs, and SMAD2/3 interact endogenously. LM2-4 cells left untreated or treated with 
TGFβ for 2 hours were probed with primary antibodies recognizing YAP/TAZ and SMAD2/3 (A), TEAD1 and TAZ 
(B), or TEAD1 and SMAD2/3 (C). In situ PLA) followed by confocal microscopy were performed using mouse and 
rabbit secondary probes. Red dots indicate endogenous interactions and nuclei were visualized with Hoechst stain. 
Representative images are shown, and three fields from each condition were quantitated, measuring the nuclear-
cytoplasmic localization of the interactions and the number of interactions per nucleus. Black error bars either 
represent the average (+SE) or the average (±SE). 
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control siRNA (siCTL) and treated with TGFβ; 2) transfected with siRNA targeting 
both YAP/TAZ (siYAP/TAZ) and treated with TGFβ; 3) transfected with siRNA 
targeting all four TEAD (TEAD1-4) family members (siTEAD) and treated with 
TGFβ; and 4) transfected with control siRNA (siCTL) and treated simultaneously 
with TGFβ and SB-431542. In terms of significant gene expression differences (p-
value < 0.01) relative to siCTL+ TGFβ treatment, 461 genes overlapped between 
siYAP/TAZ and siTEAD conditions (Figure 4.9A). This gene set displayed a high 
degree of correlation in expression (R=0.86). The expression of 594 genes 
changed following SB-431542 treatment, and of these, 176 genes overlapped with 
siYAP/TAZ conditions. Of these 176 genes, 80 were also altered following TEAD 
knockdown (Figure 4.9A). 
Interestingly, genes for which expression was altered among all three 
experimental conditions exhibited distinct expression correlations. Unbiased 
clustering segregated YAP/TAZ-TEAD- TGFβ-regulated genes into four different 
groups: Group 1 – repressed following siYAP/TAZ, siTEADs, or TGFβ inhibition 
(therefore normally induced by the presence of these factors); Group 2 – repressed 
following siYAP/TAZ or siTEAD treatment, but induced by TGFβ inhibition; Group 
3 – induced following siYAP/TAZ, siTEADs, or TGFβ inhibition (therefore normally 
repressed by the presence of these factors); and Group 4 – induced by siYAP/TAZ, 
siTEADs, but repressed by TGFβ inhibition. The top five genes of each group are 
listed in Figure 4.9A. RT-qPCR analysis confirmed sufficient knockdown in each 
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Figure 4.9 - YAP/TAZ, TEADs, and TGFβ direct different and overlapping 
transcriptional events. A. LM2-4 cells were transfected with control siRNA 
(siCTL), siRNA targeting YAP and TAZ (siY/T), or siRNA targeting all four TEADs 
(siTEAD1-4), and then treated with TGFβ or SB-431542 (SB) +TGFβ for 24 hours. 
RNA from cell lysates was harvested and global gene expression profiles were 
examined using Affymetrix microarrays. The Venn diagram highlights the number 
of genes with significant expression changes occurring for the indicated condition 
relative to the siCTL +TGFβ sample. Hierarchical clustering was performed on the 
significantly changing genes, which revealed four major clusters as indicated. Top 
significantly changing genes of interest are highlighted in each of the four 
clustering groups. B-F. LM2-4 cells were transiently transfected with siCTL, siTAZ, 
siYAP, siY/T, or siTEADs and treated with or without TGFβ or SB-431542 +TGFβ 
for 24 hours. Relative expression of genes indicated in the microarray analysis was 
determined by RT-qPCR including confirmation of knockdown (B), Group 1 genes, 
repressed by siY/T, siTEADs, and SB-431542 (SB) treatment (C), Group 2 genes, 
repressed by siY/T and siTEADs but induced by SB-431542 treatment (D), Group 
3 genes, induced by siY/T, siTEADs, and SB-431542 treatment (E), and Group 4 
genes, induced by siY/T and siTEADs but repressed by SB-431542 treatment (F). 
All data are shown as the average of three independent experiments (+SE). 
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sample (Figure 4.9B) and the microarray results for each group (Figure 4.9C-F). 
Notable genes for Group 1 included: NEGR1, UCA1, and CTGF. Elevated 
expression of the Group 1 genes NEGR1, UCA1, and CTGF relied on the presence 
of YAP/TAZ, TEADs, and active TGFβ signaling (Figure 4.9C), suggesting that 
YAP/TAZ-TEAD- TGFβ synergize to promote the expression of these genes. In 
agreement with my observations, CTGF has recently been confirmed as an 
important transcriptional target of YAP-TEAD-SMAD complexes that promotes 
tumorigenesis in human malignant mesothelioma (128). Interestingly, however, 
NEGR1, UCA1, and CTGF expression was abolished following YAP/TAZ or TEAD 
knockdown in the absence of TGFβ (Figure 4.9C), suggesting that while specific 
TGFβ signals rely on YAP/TAZ-TEAD, the basal level of YAP/TAZ-TEAD activity 
does not require TGFβ, and therefore YAP/TAZ-TEAD complexes may function 
dominantly to TGFβ signals. 
Group 2 genes I confirmed by RT-qPCR included: Occludin (OCLN) and 
Cytoplasmic FMR1-interacting protein 2 (CYFIP2) (Figure 4.9D). Group 3 genes 
confirmed included: killer cell lectin-like receptor subfamily C protein (KLRC3) and 
serine palmitoyltransferase long chain base subunit 3 (SPTLC3) (Figure 4.9E). 
Confirmed Group 4 genes included: Limb bud and heart development (LBH) and 
Prostate transmembrane protein androgen induced 1 (PMEPA1) (Figure 4.9F). 
Notably, many genes were found to be differentially regulated by YAP/TAZ-TEADs 
and TGFβ, suggesting that while YAP/TAZ-TEAD complexes synergize with some 
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TGFβ-mediated signals (Group 1 and 3 targets), they repress others (Group 2 and 
4 targets). 
NEGR1 and UCA1 are direct targets of TEADs and are necessary to maintain 
tumorigenic breast cancer phenotypes  
My analysis of LM2-4 cells indicate that YAP/TAZ, TEAD, and TGFβ co-
regulate the expression of a distinct subset of genes. To examine the importance 
of these genes in tumorigenesis I focused my attention on Group 1 genes, as these 
are synergistically induced by YAP/TAZ, TEAD, and TGFβ, and include CTGF, a 
defined mediator of YAP/TAZ-induced tumorigenesis and CSC-like phenotypes 
(12,128). The top two genes synergistically induced by YAP/TAZ-TEAD and TGFβ 
identified in my analysis were NEGR1 and UCA1. NEGR1 encodes a cell adhesion 
molecule that plays a role in neuronal growth and development (222-227). UCA1 
encodes a long non-coding RNA (lncRNA) that is expressed in development, is 
turned off in homeostatic tissues, and has been found to be re-expressed in 
bladder carcinomas (228). To determine if these are direct transcriptional targets 
of YAP/TAZ, TEAD, and SMAD2/3, I performed ChIP. Examination of the promoter 
regions of NEGR1, UCA1, and CTGF (used as a positive control) revealed 
consensus TEAD binding (229) and SMAD binding motifs (230)). ChIP of 
YAP/TAZ, TEAD, and SMAD2/3 from LM2-4 cell lysates revealed enrichment at 
these sites, with SMAD2/3 recruitment only apparent after TGFβ treatment (Figure 
4.10A-C). Thus, YAP/TAZ, TEAD, and SMAD2/3 are recruited to promoters of 
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Figure 4.10 - NEGR1, UCA1, and CTGF are direct transcriptional targets of 
YAP/TAZ, TEADs, and SMADs. LM2-4 cells treated with TGFβ or SB-431542 
(SB) were subjected to ChIP analysis using control rabbit IgG, YAP/TAZ, TEAD4, 
or SMAD2/3 antibodies. Samples were analyzed by qPCR using primers 
recognizing the indicated regions in the promoter of NEGR1 (A), UCA1 (B), or 
CTGF (C). Normalized values are shown as the average of three independent 
experiments (+SE). 
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genes identified in my studies, suggesting direct transcriptional regulation by these 
factors. 
To further investigate the role of NEGR1 and UCA1 in TGFβ-mediated 
tumorigenesis, I found that their knockdown repressed the migration of LM2-4 cells 
treated with TGFβ in wound-healing scratch assays (Figure 4.11A) and in 
transwell migration assays (Figure 4.11B). Knockdown of either NEGR1 or UCA1 
also suppressed the ability of LM2-4 cells to form large mammosphere colonies in 
the presence of TGFβ (Figure 4.12), consistent with pro-tumorigenic roles for 
NEGR1 and UCA1. The results of these experiments support my observations with 
TGFβ inhibition (SB-431542 treatment) or YAP/TAZ knockdown, suggesting that 
cooperative regulation of NEGR1 and UCA1 expression by YAP/TAZ-TEAD-
SMAD complexes is necessary to promote tumorigenic phenotypes. 
Nuclear TAZ and YAP cooperate with TGFβ to promote phenotypic and 
transcriptional changes in non-tumorigenic cells 
Based on the results from my gene expression studies, I decided to test 
whether ectopic expression of nuclear YAP/TAZ in non-tumorigenic human 
mammary MCF10A cells would lead to the induction of TGFβ-dependent 
transcriptional events similar to those I characterized in LM2-4 cells. Stable 
expression of nuclear TAZ or YAP mutants can transform epithelial cells 
(10,12,101,105), but this occurs following weeks of stable selection. Similarly, 
treatment of cells with TGFβ for several days to weeks is required to observe 
tumorigenic events in mammary epithelial cells (11,231). To prevent confounding 
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Figure 4.11 - NEGR1 and UCA1 are necessary for TGFβ-induced migration. 
A. LM2-4 cells were transiently transfected with control siRNA (siCTL) or siRNA 
targeting NEGR1 (siNEGR1) or UCA1 (siUCA1) and treated with TGFβ. 
Monolayers were wounded and analyzed for cell migration. Representative images 
of three independent experiments are shown. B. LM2-4 cells transfected with 
siCTL, siNEGR1, or siUCA1 were plated on transwell filters to assess cell 
migration. Migrated cells are shown as the average number in 10 random fields 
over two independent experiments (+SE). 
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Figure 4.12 - NEGR1 and UCA1 are necessary for TGFβ-induced 
tumorisphere formation. LM2-4 cells were transiently transfected with control 
siRNA (siCTL) or siRNA targeting NEGR1 (siNEGR1) or UCA1 (siUCA1) and 
grown under anchorage-independent conditions in the presence of TGFβ. 
Representative images of primary mammosphere colonies are shown and were 
quantitated, measuring the number of colonies formed (left) and the size of each 
colony (right). Knockdown efficiency is indicated below. Three independent 
experiments from each condition were quantitated. Black error bars represent the 
average (+SE) and red error bars represent the average (±SE). Statistics were 
performed using an unpaired Student t test and are represented as **, P < 0.005; 
***, P < 0.0001. 
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issues with long-term culture conditions, I generated MCF10A cells that express a 
nuclear-localized and stable TAZ mutant (TAZ(4SA)) (10) or YAP mutant 
(YAP(5SA)) (68) in a doxycycline-inducible manner. These YAP/TAZ mutants 
have the LATS kinase-induced phosphorylation sites substituted to alanines, 
preventing their cytoplasmic sequestration and proteasomal degradation (10,68). 
Titration of increasing amounts of doxycycline evoked subtle to high expression of 
TAZ(4SA) or YAP(5SA) in these cells (Figure 4.13A). High levels of TAZ(4SA) or 
YAP(5SA) expression for short time frames (24 hours) had minimal effects on the 
morphology of these cells (Figure 4.13B). Short treatments of TGFβ led to 
flattening of cells (Figure 4.13B), a morphology indicative of cells undergoing cell 
cycle arrest, as has been described for MCF10A cells post-TGFβ treatment (232). 
Strikingly, simultaneous doxycycline and TGFβ treatment led to rapid cell 
morphology changes that differed from either condition alone, with the cells 
becoming more spindle-like and elongated (Figure 4.13B). Further, TAZ(4SA)- or 
YAP(5SA)-expressing cells treated with TGFβ displayed much more rapid cell 
migration in a wound-healing scratch assay, as compared to either condition alone 
(Figure 4.14), indicating that nuclear YAP/TAZ synergize with TGFβ to promote 
cell morphology and cell migration changes. 
In accordance with my expression analysis of LM2-4 cells, I found that 
nuclear TAZ or YAP function in concert with TGFβ to control transcriptional events 
in MCF10A cells. For example, TAZ or YAP synergized with TGFβ to promote the 
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Figure 4.13 - Nuclear TAZ and YAP synergize with TGFβ to promote morphological changes. A. Doxycycline 
(Dox)-inducible MCF10A cells expressing 3xFLAG-TAZ(4SA) or 3xFLAG-YAP(5SA) were treated with increasing 
levels of doxycycline with or without TGFβ for 24 hours. Expression of TAZ or YAP was determined by immunoblotting 
along with GAPDH (loading control). B. Doxycycline-inducible MCF10A control cells or cells expressing TAZ(4SA) 
or YAP(5SA) were treated with doxycycline with or without TGFβ for 24 hours and examined for cell morphology. 
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Figure 4.14 - Nuclear TAZ and YAP synergize with TGFβ to promote 
migration. Doxycycline (Dox)-inducible MCF10A cells expressing 3xFLAG-
TAZ(4SA) or 3xFLAG-YAP(5SA) were treated with or without doxycycline and/or 
TGFβ for 24 hours. Monolayers were wounded and analyzed for cell migration 
after 12 hours. Representative images are shown and three independent 
experiments were quantitated. Error bars represent the average (+SE). Statistics 
were performed using an unpaired Student t test and are represented as *, P < 
0.05;  **, P < 0.01; ***, P < 0.0005. 
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transcription of Group 1 genes in an inducible fashion, including the expression of 
NEGR1, UCA1, and CTGF (Figure 4.15A). Nuclear TAZ or YAP expression also 
induced the expression of Group 2 genes (e.g. OCLN and CYFIP2), whereas 
TGFβ repressed this group of genes (Figure 4.15B). Group 4 genes on the other 
hand, specifically LBH and PMEPA1, were induced by TGFβ, but repressed in an 
inducible fashion by nuclear TAZ or YAP (Figure 4.15C). Intriguingly, Group 3 
genes were undetectable in MCF10A cells, which may reflect the more 
differentiated state of these cells compared to LM2-4 cells. Together, my data 
indicate that the relationship between YAP/TAZ and TGFβ is conserved in 
mammary-derived cells, and my observations support the idea that dysregulated 
YAP/TAZ and TGFβ work in concert to control transcriptional events. 
Nuclear TAZ and YAP overcome TGFβ-induced cytostasis in non-
tumorigenic cells 
A hallmark trait of TGFβ is its ability to suppress tumorigenesis in normal 
epithelium and early stage cancers, particularly through cell cycle inhibition. 
However, TGFβ signals lose their ability to induce cytostasis in late stage cancers 
via poorly understood mechanisms (146,147). Given that TGFβ-induced cell cycle 
arrest has been previously described in MCF10A cells (232), I sought to explore 
the relationship between TGFβ, nuclear YAP/TAZ, and cell cycle progression. I 
performed proliferation assays using control MCF10A cells or cells with 
doxycycline-inducible nuclear TAZ(4SA) or YAP(5SA) expression. TGFβ-induced 
cytostasis was evident in control MCF10A cells (Figure 4.16). Strikingly, I found 
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Figure 4.15 - Nuclear TAZ and YAP cooperate with TGFβ to regulate target 
gene transcription. Doxycycline (Dox)-inducible MCF10A cells expressing 
3xFLAG-TAZ(4SA) or 3xFLAG-YAP(5SA) were treated with increasing levels of 
doxycycline with or without TGFβ for 24 hours. Relative expression of Group 1 
genes (A), Group 2 genes (B), and Group 4 genes (C) were analyzed by RT-qPCR 
and are shown as the average of three independent experiments (±SE). 
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Figure 4.16 - Nuclear TAZ and YAP overcome TGFβ-induced cytostasis. 
Doxycycline-inducible MCF10A control cells or cells expressing 3xFLAG-
TAZ(4SA) or 3xFLAG-YAP(5SA) were treated with doxycycline with or without 
TGFβ. Cells were counted over 6 days to measure their proliferative capacity. Cells 
from three experiments were counted and the average (±SE) for each day is 
shown. This experiment was performed in collaboration with Aleks Szymaniak. 
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that expression of TAZ(4SA) or YAP(5SA) overcomes TGFβ growth arrest, as cells 
treated simultaneously with doxycycline and TGFβ proliferated similarly to control 
cells (Figure 4.16). To investigate whether the proliferative differences were due 
to cell cycle alterations, I used FACS to examine the DNA content of these cells. I 
found that TGFβ treatment arrests cells in the G1 phase of the cell cycle, while 
TAZ(4SA) or YAP(5SA) expression rescues the TGFβ induced G1 phase arrest 
(Figure 4.17A and 4.17B). Thus, my data suggest that nuclear YAP/TAZ are 
responsible for the switch in TGFβ activity from tumor suppressive to tumorigenic 
in later stage breast cancers by converging to direct a distinct transcriptional 
program (see model in Figure 4.18). 
Discussion 
I have found YAP/TAZ to be necessary for transduction of TGFβ-induced 
tumorigenic phenotypes in metastatic breast cancer cells, such as clonal 
anchorage-independent growth, cell migration, and invasion. Interactions between 
endogenous YAP/TAZ, TEAD, and SMAD2/3 in the nucleus suggest that these 
complexes coordinate their activities at the transcriptional level. Through genome-
wide expression analysis I show that YAP/TAZ, TEAD, and TGFβ regulate 
individual and common gene targets both positively and negatively, implying a 
complex level of transcriptional regulation and crosstalk between these factors. Of 
those gene targets I identified, many have yet to be characterized in breast cancer 
and therefore my work highlights previously unrecognized factors contributing to 
  113 
  
 
 
Figure 4.17 - Nuclear TAZ and YAP overcome TGFβ-induced cell cycle arrest. 
Doxycycline (Dox)-inducible MCF10A control cells or cells expressing 3xFLAG-
TAZ(4SA) or 3xFLAG-YAP(5SA) were treated with doxycycline with or without 
TGFβ. Cells were subject to propidium iodide staining and flow cytometry analysis 
to determine DNA content. Data from a representative experiment are shown (A) 
and cell cycle phase quantitation is represented as the ratio of cells in S+G2 to 
cells in G1 (B). The average of three independent experiments (+SE) is shown. 
Statistics were performed using an unpaired Student t test and are represented as 
*, P < 0.015. 
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Figure 4.18 - Model for how YAP/TAZ direct TGFβ-induced tumorigenic 
events. I propose that increased nuclear YAP/TAZ, resulting from defects in 
upstream Hippo pathway signals, overcome TGFβ-mediated tumor suppressive 
functions (e.g. cytostasis) and concomitantly drive tumorigenic transcriptional 
events by promoting the activity of TEAD-SMAD complexes. 
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tumorigenesis. Of note, EMT-related genes were not enriched among the 
overlapping YAP/TAZ-TEAD-TGFβ regulated subset, indicating that the YAP/TAZ-
TEAD-SMAD2/3 complex drives aggressive behaviors of metastatic breast cancer 
cells downstream from the loss of epithelial cell polarity. My transcriptional 
signature may thus reveal insight into the YAP/TAZ-mediated tumorigenic program 
occurring in late-stage cancers, as MDA-MB-231 cells and their LM2-4 derivatives 
possess mesenchymal properties. Indeed, the two genes that I characterized, 
NEGR1 and UCA1, proved to be necessary for the anchorage-independent growth 
and migratory properties of LM2-4 cells. YAP/TAZ and TGFβ synergistically induce 
the expression of NEGR1 and UCA1 (Group 1 genes), and given that YAP/TAZ, 
TEADs, and SMAD2/3 are enriched at the promoters of these genes, direct 
transcriptional synergy between YAP/TAZ-TEAD-SMAD complexes likely 
promotes their expression in breast cancer. 
Out of the 80 genes co-regulated by YAP/TAZ, TEAD, and TGFβ, 21 of 
them encode membrane proteins, several of which function as cell surface 
receptors, and 13 of them encode secreted proteins. The enrichment of such 
genes may reflect important non-cell-autonomous alterations that are regulated by 
YAP/TAZ-TEAD and TGFβ signals. Such signals are important for the pro-
tumorigenic activity of TAZ and YAP (233,234), and thus I propose that crosstalk 
between YAP/TAZ-TEAD and TGFβ signals demarcate a distinct local cellular 
environment that may promote a tumor-initiating niche. The well-documented 
YAP/TAZ-TEAD target CTGF encodes for a secreted factor that is cooperatively 
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induced by TGFβ. CTGF is a well-established target of TGFβ-activated SMAD2/3 
transcription factors (235), but also an important driver of YAP/TAZ-induced 
tumorigenic events (12,67). I observe that CTGF expression relies on the presence 
of YAP/TAZ, TEADs, and TGFβ signaling, and nuclear TAZ or YAP mutants 
synergize with TGFβ to strongly induce CTGF expression. Therefore, as in 
malignant mesotheliomas (128), the synergistic regulation of the CTGF promoter 
likely promotes aggressive breast cancer phenotypes. 
I have additionally identified genes that are activated by both TAZ and YAP, 
but repressed by TGFβ signaling (Group 2 genes), and reciprocally, genes 
repressed by YAP/TAZ, but induced by TGFβ (Group 4 genes). These groups of 
genes were somewhat surprising, as they indicate that YAP/TAZ and TGFβ direct 
opposing transcriptional events, and therefore suggest that a subset of TGFβ-
activated SMAD activity does not rely on YAP/TAZ, and vice versa. Based on the 
products encoded by several of these genes, I speculate that nuclear YAP/TAZ 
may override tumour-suppressive or negative feedback mechanisms initiated by 
TGFβ. For example, PMEPA1, which I found is induced by TGFβ and inhibited by 
YAP/TAZ (Group 4 gene), encodes a transmembrane protein that sequesters 
SMAD complexes in the cytoplasm (236). Thus, nuclear YAP/TAZ may function to 
overcome the induced expression of this gene to sustain pro-tumorigenic TGFβ 
signals.  
Historically TAZ and YAP have been considered to be activators of gene 
transcription. However, my data indicate that YAP/TAZ play repressive roles as 
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well (Group 3 and 4 genes). I hypothesize YAP/TAZ-TEAD complexes execute this 
repressive function by various means. Recent work has shown that YAP/TAZ 
recruit the nucleosome remodeling and deacetylation (NuRD) complex to repress 
gene expression (127). Yorkie (Yki), the homolog of YAP/TAZ in Drosophila 
melanogaster, is also known to associate with chromatin-modifying proteins 
(237,238). Thus, YAP/TAZ-TEAD complexes likely function directly to inhibit 
transcription in breast cancers through similar recruitment of repressive factors to 
control local chromatin remodeling at promoters. However, YAP/TAZ-TEAD 
complexes may also function in an indirect manner, particularly in conjunction with 
TGFβ signaling, by binding and re-localizing SMAD complexes (70,126). SMAD 
redistribution by YAP/TAZ may explain why nuclear TAZ or YAP affects the 
expression of certain target genes (Group 2 and 4) more dramatically in MCF10A 
cells in the presence of TGFβ. Moreover, YAP/TAZ binding to SMADs is evident 
in the nucleus and in the cytoplasm (Figure 4.8A), suggesting that interactions 
between these proteins in different localizations may direct distinct events.  
Of interest, nuclear TAZ or YAP is capable of overcoming TGFβ-induced 
cytostasis (Figure 4.16 and 4.17), which is a major mechanism by which TGFβ 
functions as a tumor suppressor in early stage cancers (147). Consistent with this, 
I find that constitutively nuclear YAP/TAZ is evident in breast cancer cell lines 
where TGFβ has lost its ability to induce cytostatic signals (Figure 4.1). YAP/TAZ 
drive the expression of cell cycle regulators (102), which may account for the ability 
of these factors to overcome cell cycle arrest. Indeed, my gene expression analysis 
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in LM2-4 cells identified several cell cycle regulators as YAP/TAZ-regulated genes 
(e.g. CDKL1, CCNA1, CCNB1, CCND3). However, given that YAP/TAZ bind 
SMAD complexes, I also speculate that YAP/TAZ may be capable of redirecting 
TGFβ-induced SMADs away from their cell cycle-repressive transcriptional roles 
towards those that promote tumorigenesis. 
My phenotypic and transcriptional analysis revealed redundant functions for 
TAZ and YAP. For example, TAZ and YAP have redundant roles in mediating 
TGFβ-induced mammosphere formation. Additionally, TAZ and YAP redundantly 
regulate the expression of Group 1 genes NEGR1 and UCA1 (Figure 4.9C). 
Interestingly, TAZ knockdown alone led to increases in UCA1 expression, which 
may reflect compensatory YAP hyperactivity in this context. A redundant role for 
these factors is further implied on account of similar effects resulting from nuclear 
TAZ or YAP mutant expression in MCF10A cells. Such redundancy is consistent 
with the overlapping roles of YAP/TAZ in early development (239). However, I also 
present evidence for divergent transcriptional activity, based on specific gene 
expression reliance on either TAZ or YAP exclusively. For example, the expression 
of CTGF was repressed by TAZ or YAP/TAZ knockdown in LM2-4 cells, but not by 
YAP knockdown alone (Figure 4.9C). Thus, TAZ appears to have a dominant role 
in regulating CTGF expression in LM2-4 cells. Interestingly, recent work has 
revealed that YAP, in cooperation with TGFβ, has critical roles in controlling the 
expression of CTGF in malignant mesotheliomas (128). Thus, it appears that 
context defines dominance of TAZ or YAP.  
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Effective treatments of late-stage breast cancers are lacking, and our 
current understanding of the important signals driving and maintaining proliferation 
and metastasis is unclear. My work has revealed critical intersections between 
YAP/TAZ, TEAD, and TGFβ signaling in directing pro-tumorigenic phenotypes in 
breast cancer, and provides novel mechanisms by which the TGFβ program may 
be directed towards aggressive tumorigenic phenotypes. Given the well-
documented roles of TGFβ in late-stage cancers, recent efforts have been focused 
on optimizing new TGFβ signaling inhibitors, which are currently in pre-clinical and 
clinical trials (240). While advancement with such treatments is logical, my work 
suggests that enhanced efficacy may be achieved by treatment or co-treatment 
with current (119), or future YAP/TAZ-TEAD inhibitors. 
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CHAPTER V - FUTURE DIRECTIONS, GENERAL DISCUSSION, AND 
CONCLUSION 
YAP/TAZ activated and repressed gene signatures 
In these studies, I have shown that YAP/TAZ drive pro-tumorigenic signals 
in OSCC and cooperate with TGFβ signaling to promote aggressive breast 
cancers. My work has also identified transcriptional programs associated with 
YAP/TAZ activity in both contexts. Comparing these signatures may shed light on 
the actions of YAP/TAZ in different cancers. In SCC2 cells, the activated gene 
signature is enriched for proteins involved in cell cycle regulation (Figure 5.1). 
However in LM2-4 cells, although there were a few cell cycle-regulating genes 
affected by YAP/TAZ knockdown (such as CCND3), the signature was not 
enriched for these targets. Rather, genes important for glucose, lipid, and sterol 
metabolic processes were enriched (Figure 5.1). Both aberrant cell cycle 
progression and metabolic regulation are hallmarks of cancer, and therefore 
YAP/TAZ may direct these processes differently in various contexts (5,6). These 
differences in YAP/TAZ transcriptional regulation may also reflect the distinct 
metastatic states of the SCC2 and LM2-4 cells, as the SCC2 cells originate from 
a primary tumor while the LM2-4 cells are from a metastasized lung colony. 
Interestingly, simvastatin, a statin, has recently been shown to inhibit YAP/TAZ 
nuclear activity (241,242). Simvastatin has been associated with lower breast 
cancer reoccurrence and was effective in reducing the pro-tumorigenic effects TAZ 
has on OSCCs in vitro and in vivo (243,244). This suggests different therapeutic 
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Figure 5.1 - Comparison of YAP/TAZ-regulated genes in OSCC and breast 
cancer. The Venn diagram highlights the number of genes with significant 
expression changes (genes with an FDR q-value of ≤0.05 and fold change ≥1.5 
compared with the respective control) that were identified from the microarray 
studies performed in Figure 3.8 (OSCC; SCC2 siYAP/TAZ) and Figure 4.9 (Breast 
cancer; LM2-4 siYAP/TAZ +TGFβ). Enriched gene categories are shown for the 
activated and repressed signatures from SCC2 siY/T and LM2-4 siY/T 
microarrays. Hierarchical clustering was performed on the overlapping signature, 
which revealed the majority of the genes are regulated in the same manner by 
YAP/TAZ (e.g. gene expression goes down in both SCC2 and LM2-4 samples). 
Genes of interest are highlighted to the right for several of the clusters. 
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options may be available in the treatment of YAP/TAZ associated tumors and that 
it may be beneficial to stratify patient populations based on the YAP/TAZ 
transcriptional signature to determine if the most appropriate therapy is a broad 
cell cycle inhibitor or a statin. 
Although there are clear differences in YAP/TAZ activated genes, some 
similarities are seen in the repressed gene signatures. Cell adhesion proteins were 
enriched for in both microarrays, particularly several protocadherins (PCDH) 
(Figure 5.1). Regulation of cell adhesion is complex in cancer progression, but 
changes in membrane bound proteins are associated with invasion and metastasis 
and can effect both intercellular communication as well as intracellular signaling 
pathways (245). For example, hypermethlyated PCDH clusters and reduced 
PCDH expression are associated with pediatric kidney tumors. These PCDHs 
function to suppress tumor growth in vitro partially through the inhibition of WNT 
signaling (246). The repression of these PCDH genes may reflect the control 
YAP/TAZ has not only over invasive properties via cell-cell contacts but may also 
add another layer of crosstalk with oncogenic signaling pathways. In addition, two 
cadherin-related proteins, Fat and Dachsous, are known to lie upstream in the 
Drosophila Hippo pathway to restrict Yki activity and homologs FAT and DCHS 
have been shown function similarly to direct YAP/TAZ activity in mammals (247-
249). Interestingly, changes in FAT expression have been associated with many 
different types of cancer (250). In particular, loss of FAT1 occurs in 80% of primary 
oral cancers and functions to suppress breast cancer progression (90,251,252). 
  123 
Deregulation often occurs at the genomic level through either homozygous 
deletion or promoter hypermethylation. Although I did not observe changes in FAT 
or DCHS expression in SCC2 or LM2-4 cells, perhaps another protocadherin is 
responsible for regulating YAP/TAZ activity in this context. If this is true, it could 
illustrate a feed forward mechanism YAP/TAZ use to repress upstream Hippo 
pathway components resulting in increased nuclear YAP/TAZ activity and 
unrestrained signaling. Notably, only 20% of these protocadherin genes repressed 
by YAP/TAZ were the same between SCC2 and LM2-4 cells (4 genes out of 20), 
which suggests these overlapping targets may also be important in other situations 
and further demonstrates context dependent roles for YAP/TAZ. 
Similarly, there was only 8% overlap in the YAP/TAZ differentially regulated 
genes in SCC2 and LM2-4 cells (211 overlapped out of 2575 total genes) (Figure 
5.1). Of these overlapping genes, 87% were regulated in the same way by 
YAP/TAZ (e.g. expression went down with knockdown in both microarrays). 
Identical genes regulated by YAP/TAZ in SCC2 and LM2-4 cells were not enriched 
for any particular function, although several interesting genes I have previously 
discussed are highlighted in Figure 5.1. Together, this indicates that although the 
roles for YAP/TAZ can be broadly defined as controlling proliferation, migration, 
and metastasis, the specific transcriptional functions may be context dependent. 
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The role of YAP/TAZ in the tumor microenvironment 
Angiogenesis in YAP/TAZ driven tumors 
Angiogenesis, or the formation of blood vessels, is a critical event in tumor 
formation and metastasis and is considered to be a hallmark of cancer (5,6). These 
blood vessels not only provide a source of nutrients to the primary tumor, they also 
serve as a route by which cells can metastasize to distant sites. During the growth 
and development of blood vessels, various angiogenic factors are secreted (253). 
In my transcriptional analyses, several genes encoding proteins known to induce 
angiogenesis were found as regulated by YAP/TAZ: CTGF, CYR61, and EDN1 
(254-256). These factors have been previously described as targets of YAP/TAZ 
and YAP is necessary for the induction of CTGF and EDN1 expression by TGFβ 
in mesotheliomas (67,74,128). This indicates that there are common targets that 
functionally regulate progressive tumor properties.  
Other targets of YAP/TAZ in SCC2 cells may also control angiogenesis. 
CXCL10 and CXCL14, repressed by YAP/TAZ, encode for cytokines known to 
inhibit angiogenesis (257,258). CXCL14 is also absent from tongue SCCs (257). 
Interestingly, several MMP genes were found to be repressed by YAP/TAZ and 
may contribute to the complex roles MMPs play in cancer progression (259). 
Generally MMPs are thought to promote invasive properties by remodeling the 
ECM to allow cells to migrate and can activate pro-angiogenic factors like TGFβ 
and FGF (260). However, they can also promote the processing of anti-angiogenic 
factors such as angiostatin (from plasmin/plasminogen) and endostatin (from 
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collagen XVIII) (259-261). MMP12 inhibits angiogenic properties of endothelial 
cells and vascularization (262). Contrasting effects of MMPs have also been 
observed in different contexts. For instance, MMP10 is important in the invasion 
and metastasis of head and neck cancers but its expression decreases in breast 
cancer (263,264). I see MMP10 repressed by YAP/TAZ in both OSCC and breast 
cancer. Although MMPs are generally thought to promote cancer progression, their 
tumor suppressive roles have also been revealed. MMP8 can prevent metastasis 
in melanoma and lung cancers and although MMP9 promotes breast cancer, it 
functions as a tumor suppressor in the colon by promoting Notch1 activation to 
suppress β-catenin signaling (265-267). These varying effects may explain why 
MMP inhibitors have not worked well as therapeutics (268). They may also explain 
why YAP/TAZ can function to repress MMP expression in oral and breast cancers 
and suggest that MMPs may play a tumor suppressive role in SCC2 and LM2-4 
cells. 
Although YAP/TAZ are known to control the expression of angiogenic 
factors, their functional ability in tumors to promote angiogenesis has not been well 
studied, particularly in cancer cell populations. YAP has been shown to be 
necessary in endothelial cells during development and in CAFs to promote 
angiogenesis in the tumor microenvironment (269,270). It would be interesting to 
investigate this in the orthotopic model to see if YAP/TAZ knockdown limits the 
size of the primary tumor and metastasis by inhibiting blood vessel formation. 
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YAP/TAZ in matrix stiffening and intercellular crosstalk 
The tumor microenvironment is a crucial component in the progression of 
cancer, including the rigidity of the ECM (271). Fibrotic characteristics, such as 
stiffening of the ECM through increased collagen deposition and fiber crosslinks, 
are known to correlate with tumor progression (272,273). In addition, a rigid 
microenvironment promotes nuclear YAP/TAZ activity in normal and cancer-
associated fibroblasts, which can further promote stiffening through collagen 
production and crosslinking via LOX up-regulation, creating a feed-forward loop 
(73,269). Nuclear YAP/TAZ have also been implicated in lung fibrosis and can 
overcome the limitations of a soft matrix to promote fibroblast activity (274). In 
SCC2 cells, YAP/TAZ promote the transcription of COL12A1 as well as PLOD2 
and LOXL2, which function to crosslink collagen and elastin fibers thereby 
stiffening the ECM. YAP/TAZ also repress the transcription of MMP genes, which 
may function beyond angiogenesis as discussed above, and may play a role in the 
softness of the ECM by degrading collagen and elastin fibers. 
In addition to matrix stiffness, many secreted factors may signal back and 
forth between cancer cells and CAFs (Figure 5.2). Although the sources of CAFs 
in the tumor microenvironment are not well understood, TGFβ signaling can 
promote a CAF-like phenotype in fibroblasts (275). TGFβ can also stimulate CAFs 
to secrete factors that signal to cancer cells to promote their activity (170-172). 
Similarly, secreted factors from cancer cells can signal and activate fibroblasts to 
create a feed-forward mechanism and promote an aggressive tumor
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Figure 5.2 - Crosstalk between cancer-associated fibroblasts and cancer 
cells. Cancer-associated fibroblasts and cancer cells can signal to each other 
through secreted factors and mechanical cues to promote aggressive phenotypes 
associated with nuclear YAP/TAZ activity. 
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microenvironment. Candidate signaling molecules include CTGF and CYR61, 
which may also promote angiogenesis in addition to transformed cancer cells and 
CAFs. Intercellular communication within the microenvironment has not been well 
characterized in the context of YAP/TAZ and further studies are necessary to 
better understand the signaling mechanisms. 
YAP/TAZ crosstalk with oncogenic signaling pathways in OSCC 
YAP/TAZ modulation of TGFβ signaling 
My work shows YAP/TAZ to be necessary for transduction of TGFβ-induced 
tumorigenic phenotypes in metastatic breast cancer cells (Figure 4.18). In 
addition, I have found several TGFβ targets to be regulated by YAP/TAZ in SCC2 
cells (CTGF and CYR61). YAP/TAZ may also control TGFβ signaling in this 
context through the expression of a TGFβ signaling mediator, Thrombospondin1 
(THBS1). THBS1 promotes TGFβ signaling by activating latent TGFβ complexes 
(276). In this way, nuclear YAP/TAZ may potentiate TGFβ signaling to promote 
aggressive phenotypes. Recently, TAZ was found to be necessary for TGFβ-
induced EMT events and to promote CSC populations in OSCC, similarly to what 
I have observed in breast cancer (243). This suggests that crosstalk between 
YAP/TAZ and TGFβ signals may be a common occurrence in different cancer 
types and may be necessary in maintaining a CSC niche within the tumor. It would 
also be insightful to examine the role of TGFβ in the context of YAP/TAZ-mediated 
angiogenesis and ECM remodeling to determine if TGFβ and YAP/TAZ function 
synergistically to promote other hallmarks of cancer.  
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YAP/TAZ modulation of EGFR and WNT signaling 
 YAP/TAZ can interact with other oncogenic signaling pathways besides 
TGFβ including EGFR-MAPK and WNT, although little is known about their 
crosstalk in the context of cancers. In oral cancer, EGFR expression correlates 
with progression and poor prognosis (277). In Drosophila, Yki is necessary for 
EGFR induced cell proliferation and YAP knockdown sensitizes cancer cells to 
erlotinib, an EGFR tyrosine kinase inhibitor (278,279). EGFR also controls β-
catenin localization and activity in oral cancer to promote cell cycle progression 
(280). I show that many of the genes induced by YAP/TAZ in SCC2 cells are cell 
cycle regulators and YAP/TAZ knockdown inhibits proliferation in these cells. Since 
YAP is known to control β-catenin localization and activity in other systems, it is 
possible that EGFR is signaling through YAP/TAZ and β-catenin to control cell 
cycle progression in SCC2 cells through the expression of CCND3, CCNE2, and 
CCNF (120,121). This may also explain why high nuclear YAP/TAZ confer 
chemoresistance to cetuximab, another EGFR inhibitor (97). Thus, YAP/TAZ may 
function downstream of EGFR and/or WNT and similar to TGFβ signaling, these 
signals may be dependent on nuclear YAP/TAZ activity to promote aggressive 
cancers.  
Redundancy of YAP/TAZ 
Redundancy exists between YAP and TAZ, which likely results from their 
striking homology and structural similarities (Figure 1.3) (69). My data support 
redundant functions for YAP and TAZ in both OSCC and breast cancer, as 
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knockdown of both YAP/TAZ always had a greater effect than knockdown of YAP 
or TAZ alone. Interestingly, I also found differential roles for YAP and TAZ, both in 
functional assays and in the transcriptional regulation of target genes because one 
generally had a greater effect than the other. In SCC2 cells, YAP has a dominant 
effect over TAZ while in LM2-2 cells the reverse is observed. Although YAP and 
TAZ are both expressed in each, this could reflect relative levels of YAP and TAZ 
in different cells. For instance, higher levels of YAP are seen in SCC2 cells 
compared to TAZ (Figure 3.5A). This could also result from other differences in 
YAP/TAZ interacting partners between these cells and subsequently the way each 
is regulated, similarly to the differences described between YAP1-1 and YAP1-2 
isoforms binding to p73 and angiomotin (69,79,80). Perhaps this is also why 
different activated gene signatures are observed in the SCC2 and LM2-4 cells 
discussed above. LM2-4 cells have high levels of TAZ and recently CAL27 cells 
were shown to be responsive to simvastatin treatment, cells in which I have 
observed high levels of TAZ (data not shown). On the other hand, SCC2 cells have 
high levels of YAP and an associated cell cycle transcriptional signature. Perhaps 
TAZ is responsible for an aberrant metabolic profile while YAP is responsible for 
unrestrained cell cycle activation. However at this point it is unclear how YAP and 
TAZ are differentially regulated in various cancer contexts. Elucidating this 
regulation will lead to a better understanding of the individual and redundant roles 
for YAP and TAZ and how they interact with other signals, which hopefully will aid 
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in stratifying patient tumor populations to determine appropriate therapeutic 
treatments. 
Summary of key findings and future directions 
Uncontrolled nuclear YAP/TAZ activity is known to promote aggressive 
tumorigenic phenotypes in a range of epithelial cancers (59,90). While YAP/TAZ 
are necessary for accurate tissue patterning during development, it is unclear how 
dysregulated YAP/TAZ direct transcription to induce tumorigenesis and how they 
interact with other signaling pathways during this process. Understanding the 
molecular mechanisms of nuclear YAP/TAZ is essential in the development of 
effective targeted therapeutics. 
In this thesis I present two distinct but related works examining the roles of 
YAP/TAZ in the initiation and progression of cancer. In Chapter III I asked: what 
are the actions of nuclear YAP/TAZ in oral cancers? My observations indicated 
that dysregulated YAP localization is an early event in the initiation of OSCC and 
that nuclear YAP/TAZ is necessary to drive pro-tumorigenic phenotypes both in 
vitro and in vivo. I also defined a YAP/TAZ-regulated transcriptional signature that 
correlates with changes occurring in human OSCCs. In Chapter IV I asked: do 
YAP/TAZ and TGFβ-induced signals cooperate to promote aggressive breast 
cancers and how? I found that YAP/TAZ are required for TGFβ-induced 
tumorigenic phenotypes and that these signals converge at the transcriptional level 
to control gene expression. I also defined a YAP/TAZ-TEADs-SMAD2/3-regulated 
transcriptional signature and identified two novel direct gene targets of YAP/TAZ-
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TEADs-SMAD2/3 complexes, NEGR1 and UCA1, which are necessary to maintain 
TGFβ-induced tumorigenic phenotypes. Further, I showed that nuclear YAP/TAZ 
overcome TGFβ-induced growth arrest in early cancers. Together these data 
indicate that nuclear YAP/TAZ can mediate the shift in TGFβ response from tumor 
suppressive in early stages to tumor promoting in late stage cancers. 
In both Chapter III and Chapter IV, I observed that nuclear YAP/TAZ are 
essential to maintain and promote tumorigenic phenotypes in two different origins 
of cancer. I also focused on identifying YAP/TAZ-associated transcriptional 
signatures and in Chapter V, I have compared these signatures to offer insight into 
the context-dependent transcriptional roles of nuclear YAP/TAZ. Although 
YAP/TAZ are broadly required to induce tumorigenic phenotypes, their specific 
transcriptional functions vary greatly depending on context. 
Additional questions remain regarding the role of YAP/TAZ in cancer 
initiation and progression. Particularly, it would be helpful to gain a better 
understanding of the context-dependent transcriptional events - do YAP/TAZ have 
a specific signature in every origin of cancer? What about their roles in early versus 
late stage tumors of the same origin? YAP/TAZ can interact with other signaling 
pathways and I have uncovered a relationship with TGFβ signaling in breast 
cancer. Investigating YAP/TAZ convergence with TGFβ and other signaling 
pathways across many types of cancers would be useful in understanding the 
molecular mechanisms responsible for tumorigenesis. Of the few overlapping 
YAP/TAZ-regulated gene targets, several encode for proteins that regulate 
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intercellular and extracellular events. These proteins could give insight into the 
communication occurring in the tumor microenvironment. It would also be 
interesting to better characterize the role of YAP/TAZ in non-epithelial derived cells 
in the tumor, particularly the CAF population. The last question I would like to 
propose is how is YAP/TAZ localization disrupted to promote their nuclear activity? 
Mutations in Hippo pathway components are not commonly found in cancers 
(90,105,106). Perhaps dysregulation occurs through the disruption of polarity 
complexes and upstream kinase regulation, or through mutations in other signaling 
pathways that can effect YAP/TAZ localization. In either case, a better 
understanding of both the downstream transcriptional events and the upstream 
regulation of YAP/TAZ localization will aid in identifying the most effective 
therapeutic targets. 
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